Applying Innovation, Transforming Care, Advancing Equity

January 19–21, 2023
Moscone West | San Francisco, CA | Online

Wi-Fi Network: GI23
No Password Required
gi.asco.org | #GI23
Welcome

Celebrating 20 years, the 2023 ASCO Gastrointestinal (GI) Cancers Symposium is the global forum for discussing novel ideas, practice updates, and treatment advances with leading multidisciplinary experts from around the world.

Attendees can expect:

- The presentation of the latest innovative science and solution-focused strategies in the GI cancers field.
- Featured speakers across disciplines, putting the science into context and providing a truly holistic view of the latest advances in GI cancer treatment, research, and care.
- A versatile and interactive meeting experience for both in-person and online-only attendees that allows for easy access to livestream sessions, polling and Q&A, and on-demand viewing of research presentations and slides.

For more information on how to participate in the online meeting experience, please visit gi.asco.org.
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome</td>
<td>2</td>
</tr>
<tr>
<td>Committees</td>
<td>4</td>
</tr>
<tr>
<td>Merit Award Recipients</td>
<td>5</td>
</tr>
<tr>
<td>Continuing Education and Symposium Feedback</td>
<td>5</td>
</tr>
<tr>
<td>Attendee Resources</td>
<td>6</td>
</tr>
<tr>
<td>Health and Safety</td>
<td>7</td>
</tr>
<tr>
<td>Program at a Glance</td>
<td>8</td>
</tr>
<tr>
<td>Program by Day</td>
<td>11</td>
</tr>
<tr>
<td>Poster Directory</td>
<td>20</td>
</tr>
<tr>
<td>Premium Ancillary Educational Events</td>
<td>65</td>
</tr>
<tr>
<td>Industry Expert Theater</td>
<td>68</td>
</tr>
<tr>
<td>Exhibitor Directory</td>
<td>69</td>
</tr>
</tbody>
</table>

## SAVE THE DATE

**2024 ASCO Gastrointestinal Cancers Symposium**

*January 18-20, 2024 | Moscone West | San Francisco, California | gi.asco.org*
Committees

Program Committee

George Chang, MD, MS, FACS, FASCRS (Chair)
The University of Texas MD Anderson Cancer Center

Rachna T. Shroff, MD, MS (Chair-Elect)
University of Arizona Cancer Center

Manisha Palta, MD (Immediate Past Chair)
Duke University School of Medicine

David H. Wang, MD, PhD (Leadership)
UT Southwestern Medical Center

Jamie Von Roenn, MD, FASCO (Leadership)
ASCO

Nilofer S. Azad, MD
Johns Hopkins University

Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center

Ian Chau, MD, FRCPath
The Royal Marsden NHS Foundation

Mary Feng, MD
University of California, San Francisco

William A. Hall, MD
Medical College of Wisconsin

Bryson Katona, MD, PhD
University of Pennsylvania

Wai-Keung Leung, MD, AGAF
University of Hong Kong

Marcus Noel, MD
Georgetown University

Mitchell Posner, MD
UChicago Medicine

Joel Rubenstein, MD
University of Michigan

Ugur Selek, MD, FASTRO
American Hospital Istanbul & The University of Texas MD Anderson Cancer Center

David Shibata, MD
The University of Tennessee

Karyn B. Stitzenberg, MD
The University of North Carolina at Chapel Hill

Jennifer Y. Wo, MD
Massachusetts General Hospital

Han-Kwang Yang, MD, PhD
Seoul National University

Special thanks to the Content Advisors from the American Association for the Study of Liver Diseases

Sumera Ilyas, MD
Mayo Clinic

Laura Kulik, MD
Northwestern University

Special thanks to the Content Advisors from the Society of Thoracic Surgeons

Christopher R. Morse, MD
Massachusetts General Hospital

M. Blair Marshall, MD, FACS
Brigham and Women’s Hospital
Conquer Cancer®, the ASCO Foundation, Merit Award Recipients

Conquer Cancer®, the ASCO Foundation, Merit Awards are designed to further promote quality clinical research by young scientists. A select number of Merit Awards are given annually to recognize outstanding research in abstracts submitted for presentation at the ASCO Gastrointestinal Cancers Symposium.

Ali Alqahtani, MD, Georgetown Lombardi Comprehensive Cancer Center
Ahsan Ayaz, MBBS, Mayo Clinic
Zainab Aziz, Columbia University Irving Medical Center
Alexej Ballhausen, MD, Charité–Universitätsmedizin Berlin
Neal Bhutiani, MD, PhD, The University of Texas MD Anderson Cancer Center
Timothy Brown, MD, Penn Medicine's Abramson Cancer Center
Jeremy Chang, MD, The University of California, San Diego
Darren Cowzer, MBChB, MSc, Memorial Sloan Kettering Cancer Center
Madhulika Eluri, MD, The University of Texas MD Anderson Cancer Center
Ricardo Estrada-Mendizabal, Instituto Tecnologico de Estudios Superiores de Monterrey
Claudia Fulgenzi, MD, Hammersmith Hospital, Imperial College London
Brendon Fusco, MD, Rutgers Cancer Institute of New Jersey
Marjorie Hoang, BSc, Duke-NUS Medical School
Jaewon Hyung, MD, Asan Medical Center
Thejus Jayakrishnan, MD, Cleveland Clinic Taussig Cancer Center
Fergus Keane, MBChB, MA, Memorial Sloan Kettering Cancer Center
Dong Kim, MD, Fox Chase Cancer Center
Eric Lander, MD, Vanderbilt University Medical Center
Mir Lim, MD, University of Texas Southwestern Medical Center
Lisa Liu, Fox Chase Cancer Center
Caroline Medin, MD, Emory University
Gilbert Zvikomborero Murimwa, MD, MS, University of Texas Southwestern Medical Center
Chengwei Peng, MD, New York University
Bushra Shariff, DO, Moffitt Cancer Center
Susanna Slater, MBChB, MRCP, The Royal Marsden Hospital
Joao Paulo Solar Vasconcelos, MD, University of British Colombia
Tin-Yun Tang, MD, The University of Texas MD Anderson Cancer Center
Emilie Warren, MD, Emory University
Christopher Williams, MBChB, MRCP, Leeds Cancer Center
Xianghui Zou, MD, PhD, Long Island Jewish Medical Center

Continuing Education and Symposium Feedback

Sessions at the ASCO Gastrointestinal Cancers Symposium will provide Continuing Medical Education (CME) credits and ABIM Maintenance of Certification (MOC) points for physicians. Participants should use the Program Guide to:

• Claim CME credit for sessions
• Request ABIM MOC points
• Provide feedback on sessions

Please visit conferences.asco.org/gi/continuing-education for more information about how to claim credit and request MOC points for ASCO Gastrointestinal Cancers Symposium sessions. Feedback, CME claims, and MOC requests are due by April 21, 2023.

For questions or assistance, contact customerservice@asco.org

Conflict of Interest Disclosure

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I = Immediate family member; Inst = My Institution). Disclosures are submitted per the ASCO Policy for Relationships with Companies.
Attendee Resources

Wi-Fi login instructions:
Network: GI23
No password required

Using Mi-Fi devices can negatively impact the attendee Wi-Fi experience. For the best experience for all attendees, please refrain from using your Mi-Fi device.

Use ASCO’s platform to:
- View speaker slides on your personal device in real time
- Take notes while you watch sessions
- Pose questions to faculty during sessions
- Respond to polls
- View downloadable slides and posters
- Access a dashboard to review and organize your saved content

ASCO Customer Service

ASCO Customer Service, located in the Level 1 Lobby, will be available to assist you during the following times:
- Thursday, January 19: 7:00 AM-5:45 PM
- Friday, January 20: 6:30 AM-5:30 PM
- Saturday, January 21: 6:30 AM-4:15 PM

Meeting Videos and Slides

On-demand versions of meeting videos (recordings of the sessions) and slides (downloadable slide decks) will be available to all attendees within hours following each session at meetings.asco.org.

Online Resources

The program guide, located at meetings.asco.org, is the all-in-one location for links to publications and planning tools, including:
- Interactive session tools
- Meeting videos and slides
- Abstracts and posters available for download
- Networking site (reach out to speakers and fellow attendees)
- Symposium Feedback Form, CE Request, and Certificate of Attendance

Attendees must use their ASCO.org username and password to log in to some online resources. If you need help retrieving your username and password, visit the ASCO Customer Service Desk in the Level 1 Lobby.

Posters

On-demand access to posters, their videos, and corresponding slides (video and slide content is pending presenter submission) will be available to all attendees on the morning of the session presentation at meetings.asco.org.

All posters, including online-only posters, can also be viewed at the Poster Viewing Station in the Posters, Exhibits, and Food Room.

Exhibits

ASCO encourages all attendees to visit the exhibits on Level 1 in the West Hall on Thursday, January 19 from 7:00 AM - 5:45 PM and Friday, January 20 from 7:00 AM - 5:30 PM. The exhibits offer an opportunity to extend your learning about the most advanced therapies, products, and services in cancer care. Visit gi.asco.org to view a list of exhibiting companies.

Celebrating 20 Years

2023 marks the 20th ASCO Gastrointestinal Cancers Symposium. Thank you for joining us for this milestone year! Pick up a copy of the Daily News and read their retrospective articles in addition to their coverage of the 2023 Meeting. Take a photo with your colleagues at our special interactive memory board in the Posters, Exhibits, and Food Room. Join us for cake during lunch on Thursday and make sure to try our signature cocktail during Thursday’s evening poster reception. We’ve also created commemorative buttons - find them at Registration. Don’t forget to share your memories, new and old, on social media and tag them with #GI23.

Career Opportunities

Browse available career opportunities via ASCO’s online Career Center. Use the computers at the Internet Station to easily discover open positions by location, category, or position title or search by keyword. Questions? Visit the ASCO Customer Service Desk in the Level 1 Lobby.

Breaktime With Breakthrough: ASCO in Asia

On Friday, join us in Level 1, West Hall to learn about the 2023 ASCO Breakthrough meeting program and to experience a taste of Asia. As innovations in cancer care technology accelerate progress and improve patient outcomes, ASCO Breakthrough will bring together practicing clinicians, oncology thought leaders, med-tech pioneers, novel drug developers, and research trailblazers at this can’t-miss oncology meeting. The 2023 ASCO Breakthrough meeting is scheduled for August 3-5, 2023, in Yokohama, Japan. Come learn more about the meeting, talk to clinicians and researchers who are helping to plan the program, and preview some of the amazing food and drinks the region has to offer. Can’t join us on Friday? Go to breakthrough.asco.org for more information and to sign up to receive meeting updates.
Quiet Room

A nondenominational Quiet Room is available for attendees on Level 2 in Room 2008.

Hours:
- Thursday, January 19: 7:00 AM-5:45 PM
- Friday, January 20: 6:30 AM-5:30 PM
- Saturday, January 21: 6:30 AM-4:15 PM

Nursing Room

A private room is available for use by attendees on Level 2 in Room 2006. There will be an electrical outlet and refrigerator available for attendee use. The room will be unlocked, but a “Room In Use” sign will be provided for privacy. A Mamava nursing pod is also available for attendees on Level 2 by the Howard Street restroom. Use the Mamava app to unlock and use the pod.

Hours:
- Thursday, January 19: 7:00 AM-5:45 PM
- Friday, January 20: 6:30 AM-5:30 PM
- Saturday, January 21: 6:30 AM-4:15 PM

Meeting Policies

Important policies for this Symposium, including the Attendee Code of Conduct, are available at gi.asco.org.

REMINDER: Please keep personal belongings with you at all times during the Symposium. Lost an item or found an item? Please visit the ASCO Customer Service Desk in the Level 1 Lobby.

Health and Safety

ASCO is committed to maintaining the health and safety of all 2023 ASCO Gastrointestinal Cancers Symposium attendees. Visit the Health and Safety page at gi.asco.org for the latest in-person attendee requirements and protocols.

If you have any questions about the health and safety protocols for the meeting, please visit the ASCO Customer Service Desk in the Level 1 Lobby.

ASCO and Conquer Cancer®, the ASCO Foundation, would like to thank the following major donors of the 2023 ASCO Gastrointestinal Cancers Symposium: AstraZeneca (Innovator Level) and Merck & Co., Inc. (Innovator Level).
## Program at a Glance

**Thursday, January 19**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM - 5:45 PM</td>
<td>Exhibits Open</td>
</tr>
<tr>
<td>7:00 AM - 7:50 AM</td>
<td>Complimentary Continental Breakfast</td>
</tr>
<tr>
<td>7:50 AM - 9:30 AM</td>
<td>CONTROVERSIES IN EARLY-STAGE GASTRIC AND ESOPHAGEAL CANCERS</td>
</tr>
<tr>
<td>9:30 AM - 10:00 AM</td>
<td>Break</td>
</tr>
<tr>
<td>10:00 AM - 11:00 AM</td>
<td>OTHER TARGETS IN METASTATIC ESOPHAGEAL AND GASTRIC CANCERS</td>
</tr>
<tr>
<td>11:15 AM - 12:00 PM</td>
<td>BREAKOUT SESSION: MANAGING COMPLICATIONS ACROSS TREATMENT MODALITIES**</td>
</tr>
<tr>
<td>12:00 PM - 1:30 PM</td>
<td>POSTER SESSION A: Cancers of the Esophagus and Stomach</td>
</tr>
<tr>
<td>12:15 PM - 1:15 PM</td>
<td>TRAINEE AND EARLY-CAREER NETWORKING LUNCHEON*</td>
</tr>
<tr>
<td>1:30 PM - 3:00 PM</td>
<td>ORAL ABSTRACT SESSION A: Cancers of the Esophagus and Stomach</td>
</tr>
<tr>
<td>3:00 PM - 3:30 PM</td>
<td>Break</td>
</tr>
<tr>
<td>3:30 PM - 4:45 PM</td>
<td>INTEGRATION OF IMMUNOTHERAPY ACROSS ALL LINES OF TREATMENT</td>
</tr>
<tr>
<td>4:45 PM - 5:45 PM</td>
<td>POSTER SESSION A (CONTINUED) WITH COMPLIMENTARY WINE AND CHEESE RECEPTION</td>
</tr>
<tr>
<td>5:00 PM - 5:45 PM</td>
<td>POSTER WALKS: Esophageal and Gastric Cancer and Other GI Cancers*</td>
</tr>
</tbody>
</table>

All times are in Pacific Time.

*Open to all in-person attendees. Space is limited and is available on a first-come, first-served basis.
**In-person space is limited and is available on a first-come, first-served basis. This session will be livestreamed for online attendees to watch and participate using online interactive tools.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM - 5:30 PM</td>
<td>Exhibits Open</td>
</tr>
<tr>
<td>6:30 AM - 8:15 AM</td>
<td>Complimentary Continental Breakfast</td>
</tr>
<tr>
<td>7:00 AM - 7:45 AM</td>
<td><strong>BREAKOUT SESSION: PUSHING THE ENVELOPE IN TRANSPLANT ONCOLOGY</strong></td>
</tr>
<tr>
<td>8:15 AM - 9:30 AM</td>
<td><strong>RAPID ABSTRACT SESSION B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract</strong></td>
</tr>
<tr>
<td>7:00 AM - 7:45 AM</td>
<td><strong>TARGETING THE TUMOR MICROENVIRONMENT TO OVERCOME IMMUNE RESISTANCE: STRATEGIES AND FUTURE DIRECTIONS</strong></td>
</tr>
<tr>
<td>9:30 AM - 10:00 AM</td>
<td>Break</td>
</tr>
<tr>
<td>10:00 AM - 11:00 AM</td>
<td><strong>IMAGING AND THERAPY OF NETS</strong></td>
</tr>
<tr>
<td>11:15 AM - 12:00 PM</td>
<td><strong>KEYNOTE</strong></td>
</tr>
<tr>
<td>12:00 PM - 1:30 PM</td>
<td><strong>POSTER SESSION B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract</strong> With complimentary boxed lunch</td>
</tr>
<tr>
<td>12:15 PM - 1:15 PM</td>
<td><strong>MEET THE EXPERTS NETWORKING LUNCHEON</strong> With complimentary boxed lunch</td>
</tr>
<tr>
<td>12:00 PM - 1:30 PM</td>
<td><strong>TRIALS IN PROGRESS POSTER SESSION B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract</strong> With complimentary boxed lunch</td>
</tr>
<tr>
<td>1:30 PM - 3:00 PM</td>
<td><strong>ORAL ABSTRACT SESSION B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract</strong></td>
</tr>
<tr>
<td>3:00 PM - 3:30 PM</td>
<td>Break</td>
</tr>
<tr>
<td>3:30 PM - 4:30 PM</td>
<td><strong>HOMOLOGOUS RECOMBINATION DEFICIENCY IN PANCREATICOBILIARY CANCERS</strong></td>
</tr>
<tr>
<td>4:30 PM - 5:30 PM</td>
<td><strong>POSTER SESSION B (CONTINUED) WITH COMPLIMENTARY WINE AND CHEESE RECEPTION</strong></td>
</tr>
<tr>
<td>4:30 PM - 5:30 PM</td>
<td><strong>TRIALS IN PROGRESS POSTER SESSION B (CONTINUED) WITH COMPLIMENTARY WINE AND CHEESE RECEPTION</strong></td>
</tr>
<tr>
<td>4:45 PM - 5:30 PM</td>
<td><strong>POSTER WALKS: Hepatobiliary Cancer, Pancreatic Cancer, Small Bowel Cancer, and Neuroendocrine/Carcinoid</strong></td>
</tr>
<tr>
<td></td>
<td><strong>WOMEN’S NETWORKING RECEPTION</strong></td>
</tr>
</tbody>
</table>

All times are in Pacific Time.

*Open to all in-person attendees. Space is limited and is available on a first-come, first-served basis.

**In-person space is limited and is available on a first-come, first-served basis. This session will be livestreamed for online attendees to watch and participate using online interactive tools.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 AM - 8:10 AM</td>
<td>Complimentary Continental Breakfast</td>
</tr>
<tr>
<td>6:30 AM - 4:15 PM</td>
<td>Food Room Open</td>
</tr>
<tr>
<td>6:30 AM - 7:55 AM</td>
<td><strong>POSTER SESSION C</strong>: Cancers of the Colon, Rectum, and Anus</td>
</tr>
<tr>
<td></td>
<td><strong>TRIALS IN PROGRESS POSTER SESSION C</strong>: Cancers of the Colon, Rectum, and Anus</td>
</tr>
<tr>
<td>7:00 AM - 7:45 AM</td>
<td><strong>BREAKOUT SESSION</strong>: GERMLINE GENETIC TESTING IN COLORECTAL CANCER: SHOULD IT BE PERFORMED UNIVERSALLY?**</td>
</tr>
<tr>
<td>7:45 AM - 1:30 PM</td>
<td><strong>POSTER WALKS</strong>: Anal Cancer and Colorectal Cancer*</td>
</tr>
<tr>
<td>8:10 AM - 9:30 AM</td>
<td><strong>RAPID ABSTRACT SESSION C</strong>: Cancers of the Colon, Rectum, and Anus</td>
</tr>
<tr>
<td>9:45 AM - 10:30 AM</td>
<td><strong>Rapid Abstract Session C</strong>: Cancers of the Colon, Rectum, and Anus</td>
</tr>
<tr>
<td>11:00 AM - 12:30 PM</td>
<td><strong>ORAL ABSTRACT SESSION C</strong>: Cancers of the Colon, Rectum, and Anus</td>
</tr>
<tr>
<td>12:30 PM - 2:00 PM</td>
<td><strong>POSTER SESSION C (CONTINUED)</strong></td>
</tr>
<tr>
<td></td>
<td>With complimentary boxed lunch</td>
</tr>
<tr>
<td>12:30 PM - 2:00 PM</td>
<td><strong>TRIALS IN PROGRESS POSTER SESSION C (CONTINUED)</strong></td>
</tr>
<tr>
<td></td>
<td>With complimentary boxed lunch</td>
</tr>
<tr>
<td>12:45 PM - 1:30 PM</td>
<td><strong>POSTER WALKS</strong>: Anal Cancer and Colorectal Cancer*</td>
</tr>
<tr>
<td>2:00 PM - 3:00 PM</td>
<td><strong>STATE OF THE ART NON-OPERATIVE MANAGEMENT OF RECTAL CANCER</strong></td>
</tr>
<tr>
<td>3:15 PM - 4:15 PM</td>
<td><strong>REFINEMENT OF METASTATIC COLORECTAL CANCER MANAGEMENT</strong></td>
</tr>
</tbody>
</table>

All times are in Pacific Time.

*Open to all in-person attendees. Space is limited and is available on a first-come, first-served basis.

**In-person space is limited and is available on a first-come, first-served basis. This session will be livestreamed for online attendees to watch and participate using online interactive tools.

**NEED SUPPLIES?**
Find water stations, note pads, and pens at the entrance to the General Session Room.

**NEED TO CHARGE A DEVICE?**
Power strips for charging your devices are located on the tables in the General Session Room. Additionally, if you forgot the charging cord for your phone or tablet, visit the Charging Lockers in the Posters, Exhibits, and Food Room or outside the General Session Room. The Charging Lockers have a variety of cords to fit mobile devices.
Thursday, January 19

All times are listed in Pacific Time.

7:00 AM-5:45 PM
Exhibits Open
LEVEL 1, WEST HALL

7:00 AM-7:50 AM
Complimentary Continental Breakfast
LEVEL 1, WEST HALL

7:50 AM-9:30 AM
Controversies in Early-Stage Gastric and Esophageal Cancers
LEVEL 3, BALLROOM

Mitchell C. Posner, MD—Chair
University of Chicago Medicine

Joel Rubenstein, MD, MSc—Chair
University of Michigan

George J. Chang, MD, MS
The University of Texas MD Anderson Cancer Center

Welcome of the Day
Margaret A. Tempero, MD, FASCO
UCSF Helen Diller Family Comprehensive Cancer Center

20th Anniversary Opening Remarks
Hiroyuki Ono, MD, PhD
Shizuoka Cancer Center

Expanded Indications of Endoscopic Therapy
Rishindra Reddy, MD
University of Michigan

Access to Care for Gastroesophageal Cancer
Pernilla Lagergren, PhD
Karolinska Institute

Patient-Reported Outcomes and Quality of Life After Esophagectomy

First Author: Jae Gyu Kim, MD, PhD

Moderated Panel Discussion With Drs. Posner, Rubenstein, Ono, Reddy, Lagergren, and Kim

9:30 AM-10:00 AM
Break

10:00 AM-11:00 AM
Other Targets in Metastatic Esophageal and Gastric Cancers
LEVEL 3, BALLROOM

Han-Kwang Yang, MD, PhD—Chair
Seoul National University

Keith Robert Unger, MD—Chair
Georgetown University

Najib Antoine Nassani, MD, MSc
CentraCare Digestive Center
Theranostics

Silvia Giordano, MD, PhD
University of Torino
Organoid Versus PDX for Advanced Disease

Hanneke W.M. Van Laarhoven, MD, PhD
Amsterdam University Medical Centers
Other Targeted Therapy

Case Panel: Oligometastatic Disease
Moderated Panel Discussion With Drs. Yang, Unger, Nassani, Giordano, and Van Laarhoven

11:15 AM-12:00 PM
Rapid Abstract Session A: Cancers of the Esophagus and Stomach
LEVEL 3, BALLROOM

Preresh R. Patel, MD—Chair
Winship Cancer Institute at Emory University

Elena Elimova, MD—Chair
Princess Margaret Cancer Center

ABSTRACT LBA294: INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG). (Poster Session A, Board B13)
First Author: Nick Pavlakis, PhD, FRACP, MBBS

ABSTRACT 295: Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. (Poster Session A, Board B14)
First Author: John V. Reynolds, BCh, FRCS, MA, MB, MCh

ABSTRACT 381: Five-year follow-up results of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer: JCOG1104 (OPAS-1).
First Author: Souya Nunobe, MD, PhD

ABSTRACT 305: Long-term outcomes after laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study (JCOG1401).
First Author: Shinichi Sakuramoto, MD, PhD

January 19, 2023
ABSTRACT 358: INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

First Author: Filippo Pietrantonio, MD

Panel Question and Answer

11:15 AM-12:00 PM

Breakout Session: Managing Complications Across Treatment Modalities

LEVEL 2, ROOM 2014

In-person space is limited and is available on a first-come, first-served basis. This session will be livestreamed for online attendees to watch and participate using online interactive tools.

Mary Uan-Sian Feng, MD—Chair
UCSF Helen Diller Family Comprehensive Cancer Center

Wai K. Leung, MD, MBChB—Chair
The University of Hong Kong

Hyuk-Joon Lee, MD, PhD
Seoul National University College of Medicine

Minimizing Complications Associated With Gastrectomy

Erqi L. Pollom, MD
Stanford Cancer Institute

Minimizing the Side Effects of Radiation

Yinghong Wang, MD, PhD, MS
The University of Texas MD Anderson Cancer Center

Minimizing Gastrointestinal Side Effects of Immunotherapy

Moderated Panel Discussion With Drs. Feng, Leung, Lee, Pollom, and Wang

12:00 PM-1:30 PM

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Complimentary boxed lunch provided. See p. 20 for a full listing of posters.

LEVEL 1, WEST HALL

12:00 PM-1:30 PM

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Complimentary boxed lunch provided. See p. 31 for a full listing of posters.

LEVEL 1, WEST HALL

12:15 PM-1:15 PM

Trainee and Early-Career Networking Luncheon

Complimentary boxed lunch provided. This is an in-person only networking luncheon. Space is limited and is available on a first-come, first-served basis. For more information on networking opportunities, please visit gi.asco.org.

LEVEL 2, ROOM 2018

1:30 PM-3:00 PM

Oral Abstract Session A: Cancers of the Esophagus and Stomach

LEVEL 3, BALLROOM

M. Blair Marshall, MD, FACS—Chair
Brigham and Women’s Hospital

David Cunningham, MD—Chair
The Royal Marsden NHS Foundation Trust

ABSTRACT LBA292: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study.

First Author: Kohei Shitara, MD

ABSTRACT 291: Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.

First Author: Yelena Y. Janjigian, MD

Discussion: David H. Wang, MD, PhD
University of Texas Southwestern Medical Center

ABSTRACT 290: Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.

First Author: Ken Kato, MD, PhD

ABSTRACT 289: HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma—Overall survival analysis.

First Author: Marina Maglakelidze, MD

Discussion: Jennifer Rachel Eads, MD
University of Pennsylvania

Panel Question and Answer

3:00 PM-3:30 PM

Break

3:30 PM-4:45 PM

Integration of Immunotherapy Across All Lines of Treatment

LEVEL 3, BALLROOM

Manisha Palta, MD—Chair
Duke University Medical Center

Nilofar Saba Azad, MD—Chair
Johns Hopkins University

Thierry Andre, MD
Sorbonne University and Saint-Antoine Hospital

How Do We Incorporate Immunotherapy for MSI-H Localized GI Cancers?

Anwaar Saeed, MD
University of Kansas Cancer Center

Utilization of Immune Biomarkers and TMB in Clinical Practice
Manik A. Amin, MD  
Dartmouth-Hitchcock Medical Center  
A Look at Novel Immune Therapies in GI Cancers: What’s Coming?

ABSTRACT 286: Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
First Author: Markus H. Moehler, MD, PhD

Moderated Panel Discussion With Drs. Palta, Azad, Andre, Saeed, Amin, and Moehler

4:45 PM-5:45 PM  
Poster Session A (Continued) and Trials in Progress  
Poster Session A (Continued) and Networking Reception  
Complimentary wine and cheese provided. See p. 20 for a full listing of posters.
LEVEL 1, WEST HALL

5:00 PM-5:45 PM  
Poster Walks: Esophageal and Gastric Cancer and Other GI Cancers  
This is an in-person only networking session open to all attendees. Space is limited and is available on a first-come, first-served basis. Please meet at the Poster Assistance Desk. For more information about networking opportunities please visit gi.asco.org.
LEVEL 1, WEST HALL

Ian Chau, MD—Poster Walk Leader  
The Royal Marsden NHS Foundation Trust

Mariela A. Blum Murphy, MD—Poster Walk Leader  
The University of Texas MD Anderson Cancer Center
Friday, January 20

All times are listed in Pacific Time.

7:00 AM-5:30 PM  
**Exhibits Open**  
LEVEL 1, WEST HALL

6:30 AM-8:15 AM  
**Complimentary Continental Breakfast**  
LEVEL 1, WEST HALL

7:00 AM-7:45 AM  
**Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract**  
LEVEL 3, BALLROOM

Ryan David Nipp, MD—Chair  
The University of Oklahoma Stephenson Cancer Center

Jennifer Yon-Li Wo, MD—Chair  
Massachusetts General Hospital

**ABSTRACT LBA492:** Canadian Cancer Trials Group HE.1: A phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases. (Poster Session B, Board A1)  
First Author: Laura A. Dawson, MD, FASTRO, FRCPC

**ABSTRACT 493:** Adjuvant transarterial chemoembolization with sorafenib for patients with hepatocellular carcinoma with portal vein tumor thrombus after surgery: A phase III, multicenter, randomized, controlled trial. (Poster Session B, Board A2)  
First Author: Ming Kuang

**ABSTRACT 494:** Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study. (Poster Session B, Board A3)  
First Author: Junji Furuse, MD, PhD

**ABSTRACT 662:** Celiac plexus radiosurgery for pain management in advanced cancer: An international phase II trial, health-related quality of life (HRQOL) outcomes. (Poster Session B, Board A4)  
First Author: Yaacov Richard Lawrence, MA, MBBS, MRCP

**ABSTRACT 495:** Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population. (Poster Session B, Board A5)  
First Author: Richard S. Finn, MD

Panel Question and Answer

7:00 AM-7:45 AM  
**Breakout Session: Pushing the Envelope in Transplant Oncology**  
LEVEL 2, ROOM 2014

In-person space is limited and is available on a first-come, first-served basis. This session will be livestreamed for online attendees to watch and participate using online interactive tools.

Laura Kulik, MD—Chair  
Northwestern University

Sumera Ilyas, MD—Chair  
Mayo Clinic

Gonzalo Sapisochin, MD  
Toronto General Hospital

Debate: Liver Transplantation for Intrahepatic CCA and Metastatic Colorectal Cancer: Are We There Yet?—FOR

Rafik Mark Ghobrial, MD  
Houston Methodist

Debate: Liver Transplantation for Intrahepatic CCA and Metastatic Colorectal Cancer: Are We There Yet?—AGAINST

Rebuttals and Questions From Moderators

Moderated Panel Discussion With Drs. Kulik, Ilyas, Sapisochin, and Ghobrial

8:15 AM-9:30 AM  
**Targeting the Tumor Microenvironment to Overcome Immune Resistance: Strategies and Future Directions**  
LEVEL 3, BALLROOM

William A. Hall, MD—Chair  
Medical College of Wisconsin

Florence McAllister, MD—Chair  
The University of Texas MD Anderson Cancer Center

Rachna T. Shroff, MD  
University of Arizona Cancer Center

Welcome of the Day

Gregory B. Lesinski, PhD, MPH  
Emory University

Immunology for the Clinician: Understanding the Basics

Theodore S. Hong, MD  
Massachusetts General Hospital

Clinical Trial Design and Lessons Learned in Immuno-Oncology Modulation

Luciane Tsukamoto Kagohara, PhD  
Johns Hopkins University

Dissecting the Immune Microenvironment in PDAC With Single-Cell RNA Sequencing: A Translational Science Primer for Clinicians

Stephanie Dougan  
Dana-Farber Cancer Institute

Macrophage Targeting in GI Cancers
ABSTRACT 287: Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2 (HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC).
First Author: Ali Alqahtani, MD

Moderated Panel Discussion With Drs. Hall, McAllister, Lesinski, Hong, Kagohara, Dougan, and Alqahtani

9:30 AM-10:00 AM
Break

10:00 AM-11:00 AM
Imaging and Therapy of NETS
LEVEL 3, BALLROOM

Junaid Arshad, MD—Chair
University of Arizona Cancer Center

Daneng Li, MD—Chair
City of Hope Comprehensive Cancer Center and Beckman Research Institute

Courtney Lawhn Heath, MD
University of California, San Francisco
Functional Imaging and PRRT: Practical Considerations and Future Directions

Pamela L. Kunz, MD
Yale University
Updates on Systemic Therapies
Panel Discussion: Management of Local-Regional Therapies
  → Robert Liddell, MD
  Johns Hopkins University
  Interventional Radiologist
  
  → Callisia Clarke, MD
  Medical College of Wisconsin
  Surgeon

Moderated Panel Discussion With Drs. Arshad, Li, Lawhn Heath, Kunz, Liddell, and Clarke

11:15 AM-12:00 PM
Keynote
LEVEL 3, BALLROOM

Rachna T. Shroff, MD—Chair
University of Arizona Cancer Center

Matthew Lungren, MD, MPH
Microsoft and University of California, San Francisco
Ai in Oncology

Question and Answer With Drs. Shroff and Lungren

12:00 PM-1:30 PM
Poster Session B: Cancer of the Pancreas, Small Bowel, and Hepatobiliary Tract
Complimentary boxed lunch provided. See p. 33 for a full listing of posters.
LEVEL 1, WEST HALL
3:30 PM-4:30 PM
**Homologous Recombination Deficiency in Pancreaticobiliary Cancers**

LEVEL 3, BALLROOM

*Talia Golan, MD—Chair*
Chaim Sheba Cancer Institute

*Colin D. Weekes, MD, PhD, FASCO—Chair*
Massachusetts General Hospital

*Timothy Anthy Chan, MD, PhD*
Cleveland Clinic

*Beyond PARP Inhibitors*

*Robin Kate Kelley, MD*
University of California, San Francisco
Genetic Risk in Biliary Tract Cancer

*Kim Anna Reiss, MD*
Abramson Cancer Center

*Immuno-Oncology Combinations*

*Moderated Panel Discussion With Drs. Golan, Weekes, Chan, Kelley, and Reiss*

4:30 PM-5:30 PM
**Poster Session B (Continued) and Trials in Progress**

**Poster Session B (Continued) and Networking Reception**
Complimentary wine and cheese provided.

LEVEL 1, WEST HALL

4:45 PM-5:30 PM
**Poster Walks: Hepatobiliary Cancer, Pancreatic Cancer, Small Bowel Cancer, and Neuroendocrine/Carcinoid**

This is an in-person only networking session open to all attendees. Space is limited and is available on a first-come, first-served basis. Please meet at the Poster Assistance Desk. For more information about networking opportunities please visit gi.asco.org.

LEVEL 1, WEST HALL

*Erqi L. Pollom, MD—Poster Walk Leader*
Stanford Cancer Institute
Poster Walk Leader

*Kristen Renee Spencer, DO, MPH—Poster Walk Leader*
NYU Langone Health
Poster Walk Leader

4:45 PM-5:30 PM
**Women’s Networking Reception**

This is an in-person only networking reception. Space is limited and is available on a first-come, first-served basis. For more information on networking opportunities, please visit gi.asco.org.

LEVEL 1, WEST HALL

Follow #GI23 on Twitter
Saturday, January 21

All times are listed in Pacific Time.

6:30 AM-8:10 AM
Complimentary Continental Breakfast
LEVEL 1, WEST HALL

6:30 AM-4:15 PM
Food Room Open

6:30 AM-7:55 AM
Poster Session C: Cancers of the Colon, Rectum, and Anus
See p. 50 for a full listing of posters.
LEVEL 1, WEST HALL

6:30 AM-7:55 AM
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
See p. 63 for a full listing of posters.
LEVEL 1, WEST HALL

7:00 AM-7:45 AM
Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus
LEVEL 3, BALLROOM

Sorbarikor Piawah, MD, MPH—Chair
University of California, San Francisco

Aparna Raj Parikh, MD—Chair
Massachusetts General Hospital

ABSTRACT LBA8: Botensilimab (BOT), a novel innate/adaptive immune activator, ± balstilimab (BAL; anti-PD-1) for metastatic, heavily pretreated, microsatellite stable colorectal cancer (MSS CRC). (Poster Session C, Board A1)
First Author: Anthony B. El-Khoueiry, MD

ABSTRACT 132: Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial.
First Author: Qi Lin, MD

ABSTRACT 10: Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. (Poster Session C, Board A3)
First Author: Paul Bernard Romesser, MD

ABSTRACT 11: Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. (Poster Session C, Board A4)
First Author: Kohei Shitara, MD

Panel Question and Answer

7:00 AM-7:45 AM
Breakout Session: Germline Genetic Testing in Colorectal Cancer: Should It Be Performed Universally?
In-person space is limited and is available on a first-come, first-served basis. This session will be livestreamed for online attendees to watch and participate using online interactive tools.
LEVEL 2, ROOM 2014

Bryson W. Katona, MD—Chair
Perelman School of Medicine
Introduction

Heather Hampel, MS
City of Hope National Medical Center
Debate: Germline Genetic Testing Should Be Performed Universally—FOR

Matthew B. Yurgelun, MD
Dana-Farber Cancer Institute
Debate: Germline Genetic Testing Should Be Performed Universally—AGAINST

Moderated Panel Discussion With Drs. Katona, Yurgelun, and Ms. Hampel

8:10 AM-9:30 AM
Circulating Tumor DNA: Prime Time or Jumping Too Soon?
LEVEL 3, BALLROOM

Ian Chau, MD—Chair
The Royal Marsden NHS Foundation Trust

George J. Chang, MD, MS—Chair
University of Texas MD Anderson Cancer Center

Manisha Palta, MD
Duke University Medical Center
Welcome of the Day

Jeanne Tie, MD, MBChB, FRACP
Peter MacCallum Cancer Center
Adjuvant Therapy in Colon Cancer

Kohei Shitara, MD
National Cancer Center Hospital
Metastatic Pancreaticobiliary and Gastroesophageal Cancer
Claus Lindbjerg Andersen, PhD  
Aarhus University Hospital  
Locoregional Therapy for Oligometastatic Disease

**ABSTRACT 1:** Circulating tumor DNA (ctDNA) for response assessment in patients with anal cancer treated with definitive chemoradiation.  
First Author: Janet Alvarez, MD

First Author: Janet Alvarez, MD  
Moderated Panel Discussion With Drs. Chau, George, Tie, Shitara, Andersen, and Alvarez

9:45 AM-10:30 AM  
**Keynote**  
**LEVEL 3, BALLROOM**  
Manisha Palta, MD—Chair  
Duke University Medical Center

Lorna H. McNeill, PhD, MPH  
The University of Texas MD Anderson Cancer Center  
*Equitable Solutions for Reducing Excess Mortality in Minority Populations*  
Question and Answer With Drs. Palta and McNeill

10:30 AM-11:00 AM  
**Break**

11:00 AM-12:30 PM  
**Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus**  
**LEVEL 3, BALLROOM**

Karyn Beth Stitzenberg, MD—Chair  
University of North Carolina

Van K. Morris II, MD—Chair  
The University of Texas MD Anderson Cancer Center

**ABSTRACT 4:** Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.  
First Author: Josep Tabernero, MD, PhD,

**ABSTRACT 5:** Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.  
First Author: Stacey A. Cohen, MD

Discussion: Dustin A. Deming, MD  
University of Wisconsin Carbone Cancer Center

**ABSTRACT 6:** Do nonoperative modality (NOM) treatments of rectal cancer compromise the chance of cure? Final surgical salvage results from OPERA phase 3 randomised trial (NCT02505750).  
First Author: Arthur Sun Myint, FRCP, FRCR

**ABSTRACT 7:** Long-term results from NRG-G1002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).  
First Author: Thomas J. George, MD, FACP

Discussion: Emma Holliday, MD  
The University of Texas MD Anderson Cancer Center  
Panel Question and Answer

12:30 PM-2:00 PM  
**Poster Session C (Continued) and Trials in Progress Session C (Continued)**  
With complimentary boxed lunch provided  
**LEVEL 1, WEST HALL**

12:45 PM-1:30 PM  
**Poster Walks: Anal Cancer and Colorectal Cancer**  
This is an in-person only networking session open to all attendees. Space is limited and is available on a first-come, first-served basis. Please meet at the Poster Assistance Desk. For more information about networking opportunities please visit [gi.asco.org](http://gi.asco.org).

Josep Tabernero, MD, PhD—Poster Walk Leader  
Vall d’Hebron Hospital Campus and Institute of Oncology

Jenny F. Seligmann, MBChB, PhD, MRCP—Poster Walk Leader  
University of Leeds

Rebecca KS. Wong, FRCPC—Poster Walk Leader  
Princess Margaret Cancer Center

2:00 PM-3:00 PM  
**State of the Art Nonoperative Management of Rectal Cancer**  
**LEVEL 3, BALLROOM**

David Shibata, MD—Chair  
University of Tennessee Health Science Center

Ugur Selek, MD, FASTRO—Chair  
American Hospital Istanbul and The University of Texas MD Anderson Cancer Center

Andrea Cercek, MD  
Memorial Sloan Kettering Cancer Center  
Intensifying or Substituting Chemotherapy to Maximize Eligible Patients: MMR Status Matters

Gina Brown, MD, FRCR, MRCP, MBBS  
The Royal Marsden NHS Foundation Trust  
Radiologic Biomarkers to Select Patients

Tsu Yoshi Konishi, MD  
The University of Texas MD Anderson Cancer Center  
A Surgical Viewpoint: When to Bring Out the Scalpel  
Moderated Panel Discussion With Drs. Shibata, Selek, Cercek, Brown, and Konishi

3:15 PM-4:15 PM  
**Refinement of Metastatic Colorectal Cancer Management**  
**LEVEL 3, BALLROOM**
Jennifer Yon-Li Wo, MD—Chair
Massachusetts General Hospital

Jason Denbo, MD—Chair
H. Lee Moffitt Cancer Center and Research Institute

Kai-Keen Shiu, PhD, FRCP
University College Hospital, NHS Foundation Trust
Debate: For a Fit Patient With Unresectable Metastatic RAS Wild-Type Sigmoid Colon Adenocarcinoma, First-Line EGFR Antibody Is an Essential Treatment—FOR

Ardaman Shergill, MD
University of Chicago

Debate: For a Fit Patient With Unresectable Metastatic RAS Wild-Type Sigmoid Colon Adenocarcinoma, First-Line EGFR Antibody Is an Essential Treatment—AGAINST

Cornelis J. A. Punt, MD, PhD
University Medical Center Utrecht
Intensifying Chemotherapy in mCRC: What, When, and How?

Tumor Board: Management of Recurrence After Hepatic Surgery

Alda Tam, MD
The University of Texas MD Anderson Cancer Center
Interventional Radiologist

Moderated Panel Discussion With Drs. Denbo, Wo, Shiu, Shergill, Punt, and Tam
2023 ASCO Gastrointestinal Cancers Symposium
Poster Session Directory

Thursday, January 19

12:00 PM - 1:30 PM and 4:45 PM - 5:45 PM
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
LEVEL 1, WEST HALL

Posters by Topic
Cancer Disparities (Esophageal and Gastric Cancer): B16, B17, B18
Diagnostics (Esophageal and Gastric Cancer): B19, B20
Impact of COVID-19 (Esophageal and Gastric Cancer): C1
Patient-Reported Outcomes and Real-World Evidence (Esophageal and Gastric Cancer): C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10
Prevention, Screening, and Hereditary Cancers (Esophageal and Gastric Cancer): D11
Quality of Care/Quality Improvement (Esophageal and Gastric Cancer): D12, D13, D14
Symptoms, Toxicities, and Whole-Person Care (Esophageal and Gastric Cancer): D15, D16, D17
Translational Research (Esophageal and Gastric Cancer): H18, H19, H20, J2, J3, J4, J5, J6, J7, J8, J9, J10, J11, J12, J13, J14, J15, J16, J17, J18
Tumor Biology, Biomarkers, and Pathology (Esophageal and Gastric Cancer): K1, K2, K3, K4, K5, K6, K7, K8, K9, K10, K11, K12, K13, K14, K15, K16, K17, K18, K19, L20, L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11
Other (Esophageal and Gastric Cancer): L12, L13, L14, L15, L16, L17, L18, L19
Cancer Disparities (Other GI Cancer): L20, M1, M2, M3
Patient-Reported Outcomes and Real-World Evidence (Other GI Cancer): M4, M5, M6
Prevention, Screening, and Hereditary Cancers (Other GI Cancer): M7
Quality of Care/Quality Improvement (Other GI Cancer): M8, M9
Symptoms, Toxicities, and Whole-Person Care (Other GI Cancer): M10, M11, M12
Therapeutics (Other GI Cancer): M13, M14, M15, M16, M17, M18
Translational Research (Other GI Cancer): M19, M20
Tumor Biology, Biomarkers, and Pathology (Other GI Cancer): N1, N2, N3, N4
Other (Other GI Cancer): N5, N6, N7, N8

BOARD B13 ABSTRACT LBA294: INTEGRATE Iia: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
First Author: Nick Pavlakis, PhD, FRACP, MBBS

BOARD B14 ABSTRACT 295: Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis.
First Author: John V. Reynolds, BCh, FRCS, MA, MB, MCh

BOARD B16 ABSTRACT 297: Risk of gastric cancer development according to the combination of anti-Helicobacter pylori antibody titer and degree of atrophic gastritis.
First Author: Joo Hyun Lim

BOARD B17 ABSTRACT 298: Disparities and outcomes in young adults admitted for gastric cancer in the US.
First Author: Rafaella Litvin, MD

BOARD B18 ABSTRACT 299: Differences in genomic profiles of gastric adenocarcinoma in the US and Japan.
First Author: Masaya Nakauchi, MD, PhD

BOARD B19 ABSTRACT 300: A multiplex DNA methylation assay for noninvasive early detection of gastric cancer.
First Author: Weimei Ruan

BOARD B20 ABSTRACT 301: Agreement between FGFR2 immunohistochemistry assays and fluorescence in situ hybridization (FISH) in metastatic gastric cancer: A comparison study.
First Author: Grigory A. Raskin

BOARD C1 ABSTRACT 302: Pre-diagnostic delay among patients with curative esophageal and gastric cancer during the COVID-19 pandemic.
First Author: Xin Wang, MD, PhD

BOARD C2 ABSTRACT 303: Adjuvant chemotherapy for older patients with stage II/III gastric cancer: A retrospective cohort study.
First Author: Yu-Hsuan Shih, BA
BOARD C3 ABSTRACT 304: Comparison of survival between de novo stage IV and recurrent stage IV gastric cancer.
First Author: Jun Ho Ji, MD

BOARD B11 ABSTRACT 305: Long-term outcomes after laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study (JCOG1401).
First Author: Shinichi Sakuramoto, MD, PhD

First Author: Marieke Pape, MSc

BOARD C6 ABSTRACT 307: Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz

BOARD C7 ABSTRACT 308: Role of chemotherapy in clinical T2N0M0 gastric cancer.
First Author: Sawyer Bawek, DO

BOARD C8 ABSTRACT 309: Chemotherapy-induced neuropathy in esophagogastric cancer.
First Author: Merel van Velzen, MD

BOARD C9 ABSTRACT 310: Anlotinib plus PD-1 inhibitors as chemo-free therapy in advanced or metastatic esophageal cancer: Updated results from a retrospective real-world study.
First Author: Yonggui Hong

BOARD C10 ABSTRACT 311: Symptom burden and functioning status in patients with advanced upper gastrointestinal cancers.
First Author: Xin Shelley Wang, MD, MPH

BOARD C11 ABSTRACT 312: Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.
First Author: Toshiharu Hirose, MD

BOARD C12 ABSTRACT 313: Real-world outcomes with front-line doublet versus triplet chemotherapy in advanced gastroesophageal adenocarcinoma.
First Author: Shashank Sama, MD

BOARD C13 ABSTRACT 314: Lower risk of depression after smoking cessation and alcohol abstinence in patients with gastric cancer who underwent gastrectomy: A population-based nationwide cohort study.
First Author: Bokyung Kim, MD

First Author: Vatsala Kalivar, M.B.B.S

BOARD C15 ABSTRACT 316: Optimal interval of surveillance gastroscopy after endoscopic resection for gastric neoplasia: A multicenter cohort study.
First Author: Byung-Wook Kim, MD, PhD

BOARD C16 ABSTRACT 317: Comparison of efficacy and safety of salvage-line nivolumab monotherapy between 240 and 480 mg for advanced esophageal squamous cell carcinoma.
First Author: Yuko Murashima, MD

BOARD C18 ABSTRACT 319: Real-world representativeness of patient-reported outcome measures of patients with esophagogastric cancer.
First Author: Steven C. Kuiper, MSc

BOARD D1 ABSTRACT 320: Integrating patient-reported-outcomes into prognostication in gastroesophageal cancer: Results of a population-based retrospective cohort analysis.
First Author: Thais Baccili Cury Megid, MD

BOARD D2 ABSTRACT 321: Disease-free survival (DFS) as a surrogate endpoint (SE) for overall survival (OS) in early-stage resected esophageal/gastroesophageal junction cancer (EC/GEJC): An analysis of SEER-Medicare data.
First Author: Jaffer A. Ajani, MD, FASCO

BOARD D3 ABSTRACT 322: Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.
First Author: Toru Kadono

First Author: Linde Veen, BSc

BOARD D5 ABSTRACT 324: Tumor mutational burden as a potential predictive marker for the efficacy of immunotherapy in advanced gastric cancer.
First Author: Jae Yeon Jang, MD

BOARD D6 ABSTRACT 325: Exploring real-world outcomes with nivolumab plus chemotherapy in patients with advanced gastroesophageal adenocarcinoma.
First Author: Clara Chen, PhD
POSTER SESSION A, continued

BOARD D7 ABSTRACT 326: Real-world outcome analysis of patients with advanced gastric and gastroesophageal adenocarcinoma with HER2-low expression treated with first-line therapy. First Author: Mary Frances Mulcahy, MD

BOARD D8 ABSTRACT 327: Impact of obesity on postoperative outcomes in patients undergoing esophagectomy for resectable esophageal cancer. First Author: Nikhil Patel

BOARD D9 ABSTRACT 328: Prediction of risk factors associated with readmission after robotic esophagectomy. First Author: Kenneth Lee Meredith, MD

BOARD D10 ABSTRACT 329: Multifocal early gastric neoplasms of three or more lesions versus single lesion without recurrence: A comparative study. First Author: Gyu Young Pih, Dr.

BOARD D11 ABSTRACT 330: Early detection and localization of major gastrointestinal cancers by combining DNA methylation and fragmentomic signatures generated from a single cfDNA targeted sequencing assay. First Author: Xinrong Yang, MD, PhD

BOARD D12 ABSTRACT 331: Predictors of therapeutic efficacy of anamorelin in patients with gastric, pancreatic, and colorectal cancer. First Author: Kazuhiro Shimomura

BOARD D13 ABSTRACT 332: Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade. First Author: James Tankel, MBBS

BOARD D14 ABSTRACT 333: Treatment selection and outcomes of locally advanced esophageal cancer in octo- and nonagenarians: Is a curative intent multimodal approach feasible? First Author: Nabeel Ahmed

BOARD D15 ABSTRACT 334: Lower risk of metabolic syndrome and fatty liver in gastric cancer survivors: A propensity score-matched analysis. First Author: Hyojin Park, MD

BOARD D16 ABSTRACT 335: Neoadjuvant chemoradiation in elderly Irish patients with esophageal cancer: A review of the clinical outcomes and toxicity. First Author: Ronan Andrew Mc Laughlin, MBCh, MRCPATH

BOARD D18 ABSTRACT 337: The esophageal cancer cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) + nivolumab. First Author: Akira Ooki

BOARD D19 ABSTRACT 338: Role of pretreatment absolute lymphocyte count in survival outcomes for esophageal cancer treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort. First Author: Weixiang Qi

BOARD D20 ABSTRACT 339: Gastric cancer (GC) cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) in combination with nivolumab. First Author: Kei Muro, MD

BOARD E1 ABSTRACT 340: Randomized, global, phase 3 study of tsilelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup. First Author: Eric Raymond

BOARD E2 ABSTRACT 341: Safety of ramucirumab in patients with advanced gastric cancer in Europe and North America: A prospective observational registry. First Author: Lucrezia Silvestro, MD

BOARD E3 ABSTRACT 342: The new prognostic index of advanced gastric cancer using the data from JCOG1013. First Author: Daisuke Takahari, MD, PhD

BOARD E4 ABSTRACT 343: Nab-paclitaxel combined with oxaliplatin and S1 as conversion therapy for advanced gastric adenocarcinoma. First Author: Ke Ji

BOARD E5 ABSTRACT 344: Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: A randomized clinical trial. First Author: Toshiyasu Ojima, MD, PhD

BOARD E6 ABSTRACT 345: Phase 2 study of cabozantinib (cabo) and pembrolizumab (pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) refractory to immune checkpoint inhibitors (ICIs). First Author: Farshid Dayyani, PhD

BOARD E7 ABSTRACT 346: Esophagogastrostomy with fundoplication versus double-tract reconstruction after laparoscopic proximal gastrectomy for gastric cancer. First Author: Shinta Tominaga, MD
BOARD E8 ABSTRACT 347: Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). First Author: Elena Elimova, MD

BOARD E9 ABSTRACT 348: Phase II trial evaluating the efficacy of capeOX in elderly patients with advanced gastric cancer using geriatric assessment (TCOG GI-1601). First Author: Hisashi Hosaka, MD, PhD

BOARD E10 ABSTRACT 349: Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer. First Author: Mariela A. Blum Murphy, MD

BOARD E11 ABSTRACT 350: Two cycles versus four cycles of neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, multicenter and randomized study. First Author: Qin Zhang, MD

BOARD E13 ABSTRACT 352: A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CM5901 in patients with resistant/refractory solid tumors. First Author: Rui-hua Xu, MD, PhD

BOARD E14 ABSTRACT 353: First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up. First Author: Lin Shen, MD, PhD

BOARD E15 ABSTRACT 354: A phase II study of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 followed by gastrectomy with D2 plus para-aortic nodal dissection for gastric cancer with extensive lymph node metastasis: JCOG1704. First Author: Takaki Yoshikawa, MD, PhD

BOARD E16 ABSTRACT 355: Effect of robot-assisted gastric ESD in difficult ESD locations. First Author: Sang Hyun Kim, PhD, MD

BOARD E17 ABSTRACT 356: First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study. First Author: Liangjun Zhu

BOARD E18 ABSTRACT 357: Advantages of minimally invasive surgery for remnant gastric cancer: A multi-institutional cohort study. First Author: Ryouhei Aoyama, MD

BOARD E19 ABSTRACT 358: INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). First Author: Filippo Pietrantonio, MD

BOARD E20 ABSTRACT 359: Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab-based therapy: Final results of the phase II RE-ExPEL study. First Author: Thorsten Oliver Goetze, Prof. Dr.

BOARD E21 ABSTRACT 360: Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study. First Author: Hang Yang, MD

BOARD E22 ABSTRACT 361: A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer. First Author: Philippe Alexandre Cassier, MD, PhD

BOARD E23 ABSTRACT 362: Safety and efficacy of conversion therapy for esophageal squamous cell carcinoma. First Author: Takayuki Tsuji

BOARD E24 ABSTRACT 363: SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). First Author: Yi Wang

BOARD E25 ABSTRACT 364: PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC). First Author: Xuewei Ding

BOARD E26 ABSTRACT 365: Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study). First Author: Xiaofeng Chen, Pro.
ABSTRACT 366: Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase II clinical trial.
First Author: Yan-Feng Zhang

ABSTRACT 367: Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.
First Author: Ning Li, MD

ABSTRACT 368: Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2-positive gastric cancer or solid tumors: Safety and efficacy results from a phase IId trial.
First Author: Dan Liu, MD

ABSTRACT 369: An indirect assessment of individual-level association between disease-free survival (DFS) and overall survival (OS) for resectable esophageal or gastroesophageal junction cancer (EC/GEJC): A pooled analysis of randomized controlled trials (RCTs) by an illness-death model.
First Author: Oguzhan Alagoz, PhD

ABSTRACT 370: Trimodality therapy with carboplatin/paclitaxel (CP) or FOLFOX (FFX) for esophageal/esogastric junctional cancer (EC/EGJ): Expanded safety and efficacy data from PROTECT.
First Author: Antoine Adenis, MD, PhD

ABSTRACT 371: Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACRRO GC-07).
First Author: Hiroo Ishida, MD

ABSTRACT 372: Enhancing nanoparticle paclitaxel antitumor response through targeted inhibition of c-Met pathway by merestinib in gastric cancer models.
First Author: Quinn Kaurich

First Author: Yuri Yoshinami, MD

ABSTRACT 374: Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.
First Author: Choong-kun Lee, MD, PhD

ABSTRACT 375: Safety and efficacy of prophylactic pegfilgrastim on day 3 of neoadjuvant DCF chemotherapy in elderly patients with resectable esophageal squamous cell carcinoma.
First Author: Go Ikeda, MD

ABSTRACT 376: Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial.
First Author: Ning Li, MD

ABSTRACT 377: Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.
First Author: Xiuli Yang

ABSTRACT 378: The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma.
First Author: Huilai Lv

ABSTRACT 379: Retrospective analysis of drug intake affecting the intestinal microbiota and the therapeutic effects of chemotherapy on gastric cancer.
First Author: Takeaki Nakamura, MD

First Author: Seiji Ito, MD, PhD

ABSTRACT 381: Five-year follow-up results of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer: JCOG1104 (OPAS-1).
First Author: Souya Nunobe, MD, PhD

ABSTRACT 382: Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Yakun Wang

ABSTRACT 383: Clinical outcomes of endoscopic resection of gastric GIST.
First Author: Jong-Jae Park, MD, PhD

ABSTRACT 384: Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.
First Author: Feng Wang, MD
ABSTRACT 385: The effect of potassium-competitive acid blocker tegoprazan on gastric cancer cells.
First Author: Sang Kil Lee, MD, PhD

ABSTRACT 386: Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trial
First Author: Yu Pengfei, MD

ABSTRACT 387: Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI).
First Author: Emmanuelle Samalin, MD

ABSTRACT 388: Local recurrence after curative resection of early gastric cancer by endoscopic submucosal dissection.
First Author: Moon Kyung Joo, MD, PhD

First Author: Zhi Peng, MD

First Author: Chul Hyo Jeon, MD

ABSTRACT 391: A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.
First Author: Jin Li, MD

ABSTRACT 392: Survival results by the prospectively determined clinical staging for locally advanced gastric cancer: An ancillary study of JCOG1302A (JCOG1302A2).
First Author: Tsutomu Hayashi, MD, PhD

ABSTRACT 393: A phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
First Author: Sun Young Rha, MD

ABSTRACT 394: Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
First Author: Miao Zhang

ABSTRACT 395: Long-term outcomes from adding durvalumab to neoadjuvant treatment of operable gastroesophageal cancers: Results from a multicenter study LUD2015-005.
First Author: Mark R. Middleton, PhD, FRCP

ABSTRACT 396: Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).
First Author: Xiaofeng Chen

First Author: Miaozhen Qiu

ABSTRACT 398: Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma.
First Author: Mariela A. Blum Murphy, MD

ABSTRACT 399: Endoscopic resection of gastrointestinal stromal tumor: The role of clip-and-cut endoscopic full-thickness resection.
First Author: Hwoon-Yong Jung, MD, PhD

ABSTRACT 400: Phase I trial of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.
First Author: Keun Wook Lee, MD, PhD

ABSTRACT 401: An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
First Author: Miaozhen Qiu

First Author: Tae Jun Kim, MD

ABSTRACT 403: Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.
First Author: Hwoon-Yong Jung, MD, PhD

ABSTRACT 404: Phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.
First Author: Tae-Yong Kim, MD

ABSTRACT 405: Endoscopic prediction of depth of tumor invasion in early gastric cancer in the upper third of the stomach.
First Author: Hee Seok Moon, MD
First Author: Moonwon Lee

ABSTRACT 408: A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with resectable locally advanced gastric cancer: An interim efficacy report.
First Author: Hyung-Don Kim, MD PhD

ABSTRACT 409: Anlotinib combined with paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC).
First Author: Gongqian Jiang, MD

ABSTRACT 410: Outcomes of transarterial chemoembolization in neoadjuvant therapy of patients with gastric cancer: A multicenter retrospective cohort study.
First Author: Jiang Min

First Author: Patricio Eduardo Yanez, MD

ABSTRACT 412: Endoscopic submucosal dissection in early gastric cancer with papillary histological type.
First Author: Jung Hwan Lee

ABSTRACT 413: The optimal extent of lymph node dissection for gastric cancer with para-aortic lymph node metastases.
First Author: Takeyuki Wada, MD, PhD

ABSTRACT 414: Phase I study of Minnelide and paclitaxel combination chemotherapy in refractory gastric cancer (GC).
First Author: Jeeyun Lee, MD

ABSTRACT 415: Tumor microenvironment evaluation to predict anti–PD-1 response of advanced gastric cancer: Results from a multicenter prospective clinical trial.
First Author: Wangjun Liao

ABSTRACT 416: Investigation of predictive biomarkers in patients treated with atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802).
First Author: Hideaki Bando, MD, PhD

ABSTRACT 417: Identification of HER2+ malignant cells in gastric tumors from single-cell RNAseq data.
First Author: Zhiming Zhang

First Author: Josh McGovern, BSc. (Hons)

ABSTRACT 419: MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for Oesophago-Gastric Cancer—A Randomised Maintenance Therapy Trial (PLATFORM).
First Author: Hazel Lote, MBBS, MA, MRCP, PhD

ABSTRACT 420: Inhibition of gastric cancer by a new controlled releasing compound of TLR-7/8 agonist via immune activation in a gastric cancer xenograft mice model.
First Author: Hyun Myong Kim

ABSTRACT 421: Sex differences in the clinicopathological and molecular biological features of gastric cancer.
First Author: Masanori Terashima, MD, PhD, FACS

ABSTRACT 422: Multidimensional characterization of early-stage gastric cancer: Preliminary results of MIMETIC trial.
First Author: Silvia Catanese, MD

ABSTRACT 423: Outcome prediction in resectable esophageal adenocarcinoma based on clinical variables, radiomics, and ctDNA.
First Author: Tom van den Ende, BSc, MSc

ABSTRACT 424: A novel immune monitoring platform for patients with gastrointestinal cancer.
First Author: Mojun Zhu, MD

ABSTRACT 425: LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study).
First Author: Kai Tsugaru, MD
ABSTRACT 427: Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers.
First Author: Rutika Mehta, MD, MPH

First Author: Annie Yang, MBBS

ABSTRACT 429: FGFR2-amplified gastroesophageal adenocarcinoma is a distinct genomic class: Lessons learned from a liquid biopsy platform.
First Author: Bushra Shariff

ABSTRACT 430: Ex vivo oncolytic and immune activity of CF33-hNIS-antiPDL1 against fresh peritoneal cells from patients with gastric cancer with and without peritoneal metastases.
First Author: Zhifang Zhang, PhD

ABSTRACT 431: DNA mismatch repair deficiency and outcomes of patients with resectable locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery and postoperative S-1: A sub-analysis of the phase 3 PRODIGY trial.
First Author: Jaewon Hyung, MD

ABSTRACT 432: Identification of a subpopulation of patients with gastric cancer responsive to PARP inhibitors.
First Author: Simona Corso, Associate Professor

ABSTRACT 433: The Gastric Cancer Registry Genome Explorer: A tool for genomic discovery.
First Author: Alison Figueroa Almeda, BS

ABSTRACT 434: The role of serial circulating tumor DNA for predicting clinical outcomes of chemotherapy in patients with advanced gastric cancer.
First Author: Sheehyun Kim, MD

ABSTRACT 435: CA125 kinetics as a potential biomarker for ascites progression during taxane plus ramucirumab therapy in patients with advanced gastric cancer.
First Author: Akira Ueda, MD, PhD

ABSTRACT 436: The association between trophoblast cell surface antigen 2 expression and nivolumab monotherapy in patients with advanced gastric cancer.
First Author: Toru Kadono

First Author: Toru Kadono

ABSTRACT 440: Molecular landscape and clinical implication of CCNE1-amplified esophagogastric cancer.
First Author: Ryan H. Moy, MD, PhD

ABSTRACT 441: Clinical application of circulating tumor DNA (ctDNA) in patients with metastatic gastric cancer.
First Author: Moonki Hong, MD

ABSTRACT 442: Examination of antagonistic metabolic reactions and nicotinamide/methyl nicotinamide as a biomarker in gastric cancer.
First Author: Min Shi

ABSTRACT 443: Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA).
First Author: Avani Athauda, MBBS, MRCP

ABSTRACT 444: Serum IL-6 level to predict survival and treatment response in gastric and gastroesophageal junction cancer.
First Author: John D. Karalis, MD

ABSTRACT 445: CA125 kinetics as a potential biomarker of prognosis in nivolumab monotherapy for patients with advanced gastric cancer and peritoneal metastasis.
First Author: Takayuki Ando, MD, PhD

ABSTRACT 446: Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable esophagogastric adenocarcinoma (OGA).
First Author: Anderley Gordon
ABSTRACT 448: Proposal of a coagulation score to predict postoperative survival of patients undergoing neoadjuvant therapy followed by subtotal esophagectomy for squamous cell carcinoma of the esophagus.
First Author: Fumitake Sugiyama

ABSTRACT 449: Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).
First Author: Ansh Kapil, MS

ABSTRACT 450: Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer.
First Author: Maira Soto, PhD

ABSTRACT 451: Molecular profiling of gastric neuroendocrine carcinomas.
First Author: Ko Ikegame, MD

ABSTRACT 452: Circulating tumor DNA as a marker of recurrence risk in locoregional esophagealgastric cancers with pathologic complete response.
First Author: Eric Michael Lander, MD

ABSTRACT 453: Clinical significance of D-amino acid profile for cancer detection in early stage and prediction of efficacy of nivolumab in gastric cancer.
First Author: Kai Tsugaru, MD

ABSTRACT 454: IL-1β and IL-6 as predictors of ypN and early response to neoadjuvant chemotherapy in patients with locally advanced GC and GEJ cancer.
First Author: Katarzyna Marcisz-Grzanka, MD

ABSTRACT 455: Malignant ascites as a marker of peritoneal carcinomatosis burden in patients with colorectal and gastroesophageal cancer.
First Author: Yong Xiang Gwee, MBBS

First Author: Tae-Yong Kim, MD

ABSTRACT 457: Genomic and immune landscape of ERBB2/ERBB3 alterations in gastroesophageal adenocarcinoma.
First Author: Sarbajit Mukherjee, MD, MS

ABSTRACT 458: Unique microbial profile identified in patients with gastric cancer with pathologic response to neoadjuvant chemotherapy.
First Author: Harrison M. Drebin, BA

ABSTRACT 459: Clinicopathological features of HER2-low expressed advanced gastric cancers.
First Author: Izuma Nakayama, MD, PhD

First Author: Shun Nakamura, MD

ABSTRACT 461: Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum chemotherapy for metastatic, recurrent, or locally advanced unresectable gastric cancer.
First Author: Chung Ryl Oh

ABSTRACT 462: Immunohistochemistry-based molecular classification of gastric cancer in India. How are we different?
First Author: Biswajit Dubashi, DNB, DM

ABSTRACT 463: Effect of PD-1 inhibition on macrophage population in human tissue cultures.
First Author: Ngoc Hoang, Master of Science

ABSTRACT 464: Gene expression profiles in Hispanic patients with early-onset gastric cancer.
First Author: Michelle R Ju, MD

ABSTRACT 465: Nomogram to predict peritoneal dissemination in gastric cancer.
First Author: Prasanth Penumadu, MCh

ABSTRACT 466: Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.
First Author: Diarmuid Martin Moran, PhD

First Author: Kush Gupta, MD

ABSTRACT 468: Development of a postoperative nomogram to predict overall survival in gastric cancer using variables the AJCC recommends for collection and registration.
First Author: Etsuro Bando, MD, PhD

ABSTRACT 469: Dosimetric comparison of target volume coverage and sparing of organs at risk (OARs) between helical intensity modulated radiotherapy (HI-IMRT) versus volumetric arc therapy (VMAT) for mid and lower thoracic oesophageal carcinoma.
First Author: Vatsala Yagnik, DNB
ABSTRACT 470: The role of education in adjusting to changes in clinical practice for gastric or gastroesophageal junction adenocarcinomas.
First Author: Tariqa Ackbarali, PhD, MS

First Author: Hee Man Kim, MD, PhD

ABSTRACT 472: Clinicopathologic features of early-onset (EO) esophageal and gastric cancers.
First Author: Sarah Elizabeth Lochrin

ABSTRACT 473: Time to first treatment and optimal adjuvant treatment strategy in patients with resectable gastric cancer pathologically upstaged to lymph node–positive disease.
First Author: Pranay Shah Ajay, MD

ABSTRACT 785: The role of socioeconomic deprivation in gastrointestinal cancer clinical trial enrollment at an NCI-designated comprehensive cancer center.
First Author: Daniel Strebig

ABSTRACT 786: Demographic and regional trends of gastrointestinal (GI) cancer mortality in adolescents and young adults (AYA) in the US, 1999-2019.
First Author: S. M. Qasim Hussaini, MD, MS

ABSTRACT 787: Social vulnerability and survival in GI cancers.
First Author: Gilbert Z. Murimwa, MD, MS

First Author: S. M. Qasim Hussaini, MD, MS

ABSTRACT 789: Continuous maintenance (Maint) capecitabine (Cape) dosing for colorectal (CRC) and pancreatic cancers (PC): A single-institution, retrospective, real-world study.
First Author: Reetu Mukherji, MD

ABSTRACT 790: Effect of tumor location on the efficacy of chemotherapy for gastrointestinal stromal tumors.
First Author: Ryan Sweeney, MD

ABSTRACT 791: Identification of risk factors for gastrointestinal irAEs associated with immune checkpoint inhibitors.
First Author: Ryo Morikawa

ABSTRACT 792: Risks and implications of multiple actionable pathogenic germline variants discovered by panel-based cancer predisposition testing.
First Author: Michael J. Hall, MD

ABSTRACT 793: Use of positron emission tomography-computed tomography (PET-CT) scan in patients with gastrointestinal (GI) cancer at the University Hospital of Montreal (CHUM).
First Author: Ahmad Gebai

ABSTRACT 794: Defining equitable genomic testing uptake in gastrointestinal oncology: Ensuring capture of demographic data.
First Author: Elliana K. Haakenstad, MPH

ABSTRACT 795: Efficacy and tolerability of immune checkpoint inhibitors in elderly patients with MSI/dMMR gastrointestinal cancers and impact of toxicities on efficacy: The immunoMSI cohort.
First Author: Leah Maily-Giacchetti

ABSTRACT 796: Systemic anti-cancer therapy in older patients with gastrointestinal malignancies following comprehensive geriatric assessment: An age-based subgroup analysis.
First Author: Caityriona Goggin, MB BCH BA0

First Author: Bei Jiang, MD, PhD

ABSTRACT 798: Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang, MD

ABSTRACT 799: Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study.
First Author: Bo Zhang, MD

ABSTRACT 800: The efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: A multicenter, retrospective study.
First Author: Weili Yang

First Author: Olisaemeka Ogbue, MD

ABSTRACT 802: A phase II clinical trial of toripalimab in advanced solid tumors with POLE/POLD1 mutation.
First Author: Ying Jin
**POSTER SESSION A, continued**

**BOARD M18**  
**ABSTRACT 803**: Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, open-label study in China.  
First Author: Jian Li

**BOARD M19**  
**ABSTRACT 804**: The relationship between CT-derived sarcopenia, systemic inflammation, physical function and survival in patients with advanced cancer.  
First Author: Josh McGovern, BSc. (Hons)

**BOARD M20**  
**ABSTRACT 805**: Success rates and clinicopathologic associations with experimental outcomes of a novel circulating tumor cell (CTC) technology in advanced colon cancer (CC) and pancreatic cancer (PC).  
First Author: Reetu Mukherji, MD

**BOARD N1**  
**ABSTRACT 806**: Prevalence and genomic landscape of BRAF alterations across gastrointestinal cancers.  
First Author: David Driscoll, PhD

**BOARD N2**  
**ABSTRACT 807**: The Wnt signaling pathway in gastrointestinal cancers.  
First Author: Zoran Gatalica, MD

**BOARD N3**  
**ABSTRACT 808**: Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic non-colorectal gastrointestinal cancers.  
First Author: Amit Mahipal, MBBS, MPH

**BOARD N4**  
**ABSTRACT 809**: Is liquid biopsy useful in patients with GI malignancies and exclusive peritoneal disease?  
First Author: Cristina Smolenschi, MD

**BOARD N5**  
**ABSTRACT 810**: Preoperative frailty to predict short-term outcomes in patients with cancer.  
First Author: Nazanin Khajoueinejad, MD

**BOARD N6**  
**ABSTRACT 811**: Perioperative changes in geriatric functions of elderly patients undergoing surgical resection for gastric cancer.  
First Author: Chie Tanaka, MD

**BOARD N7**  
**ABSTRACT 812**: Epidemiology and survival analysis of non-GIST GI sarcomas: A two-decade analysis of SEER database.  
First Author: Snigdha Nutalapati, MD

**BOARD N8**  
**ABSTRACT 813**: Factors associated with weekend emergency department visits in patients with GI cancer.  
First Author: Jay Parekh

Follow #GI23 on Twitter
Thursday, January 19

12:00 PM - 1:30 PM and 4:45 PM - 5:45 PM
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
LEVEL 1, WEST HALL

Posters by Topic
Therapeutics (Esophageal and Gastric Cancer): N9, N10, N11, N12, N13, N14, N15, N16, N17, N18, N19, N20, P1, P2
Other (Esophageal and Gastric Cancer): P3
Therapeutics (Other GI Cancer): P4, P5, P6, P7, P8
Translational Research (Other GI Cancer): P9
Other (Other GI Cancer): P10

BOARD N9 ABSTRACT TPS474: A multicenter randomized controlled trial of esophagectomy with or without prophylactic supraclavicular node dissection: A phase III trial (JCOG2013, MODERN3). First Author: Shigeru Tsunoda, MD, PhD, FACS

BOARD N11 ABSTRACT TPS476: TST001 (a high affinity humanized anti-claudin18.2 monoclonal antibody) in combination with nivolumab plus capecitabine and oxaliplatin as first-line or with nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer: Design of cohorts from a phase I/IIa study (TST001-1002). First Author: Weijian Guo, MD, PhD

BOARD N12 ABSTRACT TPS477: Combined intraperitoneal and systemic chemotherapy as adjuvant or perioperative chemotherapy for patients with type 4 scirrhous gastric cancer: PHOENIX-GC2 trial. First Author: Hironori Ishigami, MD, PhD

BOARD N13 ABSTRACT TPS478: A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. First Author: Martin Gutierrez, MD

BOARD N14 ABSTRACT TPS479: Single-arm phase II trial to evaluate the safety of laparoscopic/robotic total gastrectomy with spleen-preserving splenic hilar dissection for locally advanced proximal gastric cancer that invades the greater curvature. JCOG1809. First Author: Takahiro Kinoshita, MD

BOARD N15 ABSTRACT TPS480: A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2-targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma. First Author: David Bing Zhen, MD

BOARD N16 ABSTRACT TPS481: nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment. First Author: Timothy Jay Price, DHSc, MBBS, FRACP

BOARD N17 ABSTRACT TPS482: Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress. First Author: Wei Wang

BOARD N18 ABSTRACT TPS483: Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs). First Author: Suzanne George, MD

BOARD N19 ABSTRACT TPS484: Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ, DisTinGuish). First Author: Keun Wook Lee, MD, PhD

BOARD N20 ABSTRACT TPS485: Perioperative penpulimab plus anlotinib combined with chemotherapy for locally advanced gastric cancer: A single arm, multicenter, phase II clinical trial. First Author: Mian Wang

BOARD N21 ABSTRACT TPS486: Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as adjuvant therapy in ctDNA-positive gastric and esophagogastrectomy adenocarcinoma: A protocol for a randomized, controlled, multicenter phase II clinical trial—EXPLORING study. First Author: Yizhang Chen
ABSTRACT TPS487: KEYMAKER-U06 substudy 06A trial in progress: A phase 1/2 study of investigational agents with pembrolizumab (pembro) plus chemotherapy (chemo) or lenvatinib in PD-1/L1 treatment-naive advanced esophageal cancer.
First Author: Ken Kato, MD, PhD,

ABSTRACT TPS488: A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).
First Author: Changying Guo

ABSTRACT TPS814: A phase I study of a mutant KRAS-targeted long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer and MMR-proficient metastatic colorectal cancer.
First Author: Saurav Daniel Haldar, MD

ABSTRACT TPS816: A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.
First Author: Benjamin L. Schlechter, MD

ABSTRACT TPS817: A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).
First Author: Hewitt Chang, BA

ABSTRACT TPS818: Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).
First Author: Dustin A. Deming, MD

ABSTRACT TPS819: A prospective translational study investigating the association of gut microbiome (GM) diversity with pathological complete response (pCR) after neoadjuvant treatment in early stage rectal and esophageal cancers.
First Author: Ronan Andrew Mc Laughlin, MBBCh, MRCPATH

ABSTRACT TPS820: A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers.
First Author: Scott Kopetz, MD, PhD
12:00 PM - 1:30 PM and 4:30 PM - 5:30 PM

**Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract**

**LEVEL 1, WEST HALL**

**Posters by Topic**

**Cancer Disparities (Hepatobiliary Cancer):** A6, A7, A8, A9, A10

**Diagnostics (Hepatobiliary Cancer):** A11, A12

**Patient-Reported Outcomes and Real-World Evidence (Hepatobiliary Cancer):** A1, A5, A13, A14, A15, A16, A17, A18, A19, A20, B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B14, B15

**Prevention, Screening, and Hereditary Cancers (Hepatobiliary Cancer):** B16

**Quality of Care/Quality Improvement (Hepatobiliary Cancer):** B17, B18

**Symptoms, Toxicities, and Whole-Person Care (Hepatobiliary Cancer):** B19, B20

**Therapeutics (Hepatobiliary Cancer):** A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B14, B15, B16, B17, B18, B19, B20, C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, E1, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11, E12, E13, E14, E15, E16, E17, E18, E19, E20

**Translational Research (Hepatobiliary Cancer):** F1, F2, F3, F4, F5, F6

**Tumor Biology, Biomarkers, and Pathology (Hepatobiliary Cancer):** F7, F8, F9, F10, F11, F12, F13, F14, F15, F16, F17, F18, F19, F20, G1, G2

**Other (Hepatobiliary Cancer):** G3, G4, G5, G6, G7, G8, G9

**Translational Research (Neuroendocrine/Carcinoid):** G10

**Patient-Reported Outcomes and Real-World Evidence (Neuroendocrine/Carcinoid):** G11, G12, G13

**Therapeutics (Neuroendocrine/Carcinoid):** G14, G15, G16, G17

**Translational Research (Neuroendocrine/Carcinoid):** G18, G19

**Tumor Biology, Biomarkers, and Pathology (Neuroendocrine/ Carcinoid):** G20, H2, H3, H4, H5, H6

**Cancer Disparities (Pancreatic Cancer):** H7, H8, H9, H10, H11, H12

**Diagnostics (Pancreatic Cancer):** H13, H14, H15, H16

**Patient-Reported Outcomes and Real-World Evidence (Pancreatic Cancer):** H17, H18, H19, H20, J1, J2, J3, J4, J5, J6, J7, J8, J9, J10, J11

**Prevention, Screening, and Hereditary Cancers (Pancreatic Cancer):** J12, J13, J14, J15, J16

**Quality of Care/Quality Improvement (Pancreatic Cancer):** J17, J18, K1, K2

**Symptoms, Toxicities, and Whole-Person Care (Pancreatic Cancer):** K3, K4, K5, K6, K7

**Therapeutics (Pancreatic Cancer):** A4, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B14, B15, B16, B17, B18, B19, B20, C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, E1, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11, E12, E13, E14, E15, E16, E17, E18, E19, E20

**Translational Research (Pancreatic Cancer):** L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18

**Tumor Biology, Biomarkers, and Pathology (Pancreatic Cancer):** M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, N1

**Other (Pancreatic Cancer):** N2, N3, N4

**Patient-Reported Outcomes and Real-World Evidence (Small Bowel Cancer):** N5
ABSTRACT 502: Utility of AST to platelet ratio index (APRI) score in predicting post-surgical outcomes in patients with cholangiocarcinoma.
First Author: Faaiq Nabeel Aslam, BS

ABSTRACT 503: Extending surgical resection for hepatocellular carcinoma beyond Barcelona Clinic for Liver Cancer (BCLC) stage A: A novel application of the modified BCLC staging system.
First Author: Ian Wee, MBBS

ABSTRACT 504: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).
First Author: Linda Wu, MD

ABSTRACT 505: Real-world treatments and outcomes of resected biliary tract cancers in British Columbia, Canada.
First Author: Mélina Boutin

ABSTRACT 506: Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
First Author: Josep M Llovet, MD, PhD

ABSTRACT 507: Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma.
First Author: Jennifer Gile, MD

ABSTRACT 508: Impact of etiology of hepatocellular carcinoma on treatment outcomes in a real-world database.
First Author: Timothy J. Brown, MD

First Author: Shaohua Li, MD

First Author: Yoshinari Asaoka, MD, PhD

ABSTRACT 511: Prevalence of historical medical conditions or comorbidities with potential role in clinical decision making related to suitability of immune-oncologic plus IV antiangiogenic therapy in newly diagnosed first-line unresectable hepatocellular carcinoma in the United States.
First Author: Tammy Schuler, PhD

ABSTRACT 512: A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
First Author: Kazufumi Kobayashi, MD, PhD

ABSTRACT 513: Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer, MBBCh, MSc

ABSTRACT 514: Incidence and costs associated with clinically significant events in real-world patients with unresectable hepatocellular carcinoma on systemic therapy.
First Author: Marcus Healey, PhD, MBA, MSc

ABSTRACT 515: Etiologies of cirrhosis by ethnicities of patients with hepatocellular carcinoma.
First Author: Jeremy Chang, MD

ABSTRACT 516: Immunohistochemical and genetic profiles do not predict behavior of mixed hepatocellular intrahepatic cholangiocarcinoma.
First Author: Santiago Sucre, MD

ABSTRACT 517: Clinical and prognostic utility of ALBI versus Child-Pugh score in a Mexican population with hepatocellular carcinoma.
First Author: Maria del Consuelo Diaz Romero, MD

First Author: Richard S. Finn, MD

ABSTRACT 519: The real-world prevalence of esophagogastric varices, bleeding, emergency room visits, and hospitalization among patients with advanced hepatocellular carcinoma in the US.
First Author: Neehar Parikh, MD, MS

ABSTRACT 520: An active trend of immunotherapy combination regimen as second-line therapy for advanced biliary tract cancer: A multicenter retrospective study.
First Author: Jieer Ying

ABSTRACT 521: An observational study of best supportive care with or without oral capecitabine in patients with metastatic gallbladder cancer.
First Author: Shaleen Kumar, MD

First Author: Mélina Boutin
BOARD B13 ABSTRACT 523: Short- and long-term real-world survival for metastatic bile duct cancer, 2000 to 2018. First Author: Sarah Jeanne Wood, MD

BOARD B14 ABSTRACT 524: Treatment patterns and oncologic outcomes of carcinoma of the ampulla of vater in a reference hospital in a middle-income country: A real-world-based study. First Author: Abdel Karim Dip Borunda, MD

BOARD B15 ABSTRACT 525: Influence of clinical and tumor characteristics on survival in patients with hepatocellular carcinoma with bone metastasis. First Author: Muhammet Ozer, MD

BOARD B16 ABSTRACT 526: Attitudes toward prevention options in Lynch syndrome (LS): Comparing frameshift peptide vaccination (FSPVAX), colonoscopy (COLO), and aspirin (ASA) chemoprevention. First Author: Michael J. Hall, MD

BOARD B17 ABSTRACT 527: Primary percutaneous stenting above the ampulla for palliative biliary drainage of malignant hilar biliary obstruction. First Author: Stijn Franssen, MD

BOARD B18 ABSTRACT 528: Promoting multidisciplinary care for patients with unresectable hepatocellular carcinoma (HCC): Findings from a quality improvement initiative across two community cancer centers. First Author: Ari David Baron, MD

BOARD B19 ABSTRACT 529: Benefits of measuring urinary protein/creatinine ratio in lenvatinib treatment for unresectable hepatocellular carcinoma. First Author: Koki Morishita

BOARD B20 ABSTRACT 530: Report of adverse events of special interest (AEs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma. First Author: Zhenggang Ren

BOARD C1 ABSTRACT 531: Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer. First Author: Mohamed Bouattour, MD

BOARD C2 ABSTRACT 532: A multi-center study to investigate the role of sarcopenia as a prognostic factor in patients with hepatocellular carcinoma treated by trans-arterial radioembolization. First Author: Heechul Nam

BOARD C3 ABSTRACT 533: A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1. First Author: Masayuki Furukawa, MD, PhD

BOARD C4 ABSTRACT 534: A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC). First Author: Ashwin Somasundaram, MD

BOARD C5 ABSTRACT 535: Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study. First Author: Masatoshi Kudo, MD, PhD

BOARD C6 ABSTRACT 536: Downstaging locally advanced hepatocellular carcinoma with selective internal radiation therapy. First Author: Marjorie Hoang, BSc

BOARD C7 ABSTRACT 537: A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study. First Author: Jamie Partridge, PhD, MBA

BOARD C8 ABSTRACT 538: IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study. First Author: Masatoshi Kudo, MD, PhD

BOARD C9 ABSTRACT 539: Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis. First Author: Milind M. Javle, MD

BOARD C10 ABSTRACT 540: CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study. First Author: Do-Youn Oh, MD, PhD

BOARD C11 ABSTRACT 541: Risk factors for early relapse in patients with biliary tract cancers who underwent curative resection: An exploratory subgroup analysis of JCOG1202. First Author: Hiroaki Yanagimoto, MD, PhD
ABSTRACT 542: Clinical utility of comprehensive genomic profiling in patients with unresectable primary liver cancer.
First Author: Shun Ishido, MD

ABSTRACT 543: Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/ib dose-escalation/expansion trials.
First Author: Noboru Yamamoto, MD, PhD

ABSTRACT 544: Bevacizumab combined with atezolizumab or sintilimab as second-line treatment in patients with advanced hepatocellular carcinoma: A retrospective study.
First Author: Leijuan Gan

ABSTRACT 545: Randomized phase 2 study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy inpretreated patients with metastatic biliary tract cancer.
First Author: Alice Markussen, MD

ABSTRACT 546: Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Timothy Lewis Cannon, MD

ABSTRACT 547: Early tumor shrinkage as a predictor of survival in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407.
First Author: Shun Tezuka, MD, PhD

ABSTRACT 548: Comparison of clinical features by primary sites in patients with biliary tract cancer who received gemcitabine-based chemotherapy: An exploratory analysis of JCOG1113.
First Author: Yuko Suzuki, MD, PhD

ABSTRACT 549: Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.
First Author: Claudia A.M. Fulgenzi

ABSTRACT 550: Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study.
First Author: Aiwu Ruth He, MD, PhD

ABSTRACT 551: Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
First Author: Oxana V. Crysler, MD

ABSTRACT 552: Malignant portal vein tumor thrombosis (PVTT) in patients with hepatocellular (HCC) carcinoma: Insights from a Western single-institutional cohort.
First Author: Sindhu Vikash

ABSTRACT 553: Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
First Author: Chloe Lim, MD

First Author: Jaekyung Cheon, MD

ABSTRACT 555: IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel, MD

ABSTRACT 556: Safety of drug-eluting beads transarterial chemoembolization under the combination therapy with immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
First Author: Sung-Hua Chiu, MD

ABSTRACT 557: Efficacy of atezolizumab/bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma (HCC) according to the type of disease progression.
First Author: Spyridon Pantziros

ABSTRACT 558: Efficacy of atezolizumab/bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma (HCC) according to the type of disease progression.
First Author: Tingbo Liang, MD

ABSTRACT 559: Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage.
First Author: Jeremy Sharib, MD
ABSTRACT 561: Liver-directed combined radiotherapy for downstaging of over the Milan advanced hepatocellular carcinoma converting to liver transplantation.
First Author: Yong Tae Kim

ABSTRACT 562: Combined transarterial chemoembolization and external beam radiotherapy for identifying surgical candidates for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score-weighted analysis.
First Author: Sang MIN Yoon, MD, PhD

ABSTRACT 563: The impact of peri-operative chemotherapy on the outcomes of patients with non-metastatic cholangiocarcinoma.
First Author: Firas Baidoun, MD, FACP

ABSTRACT 564: Nab-paclitaxel plus anti-PD-1 antibody as second-line treatment for advanced biliary tract cancer: An investigator-initiated phase 2 study (NapaSinti trial).
First Author: Xiaofen Li

First Author: Jinsil Seong, MD, PhD

ABSTRACT 566: Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study.
First Author: Masaumi Ikeda, MD, PhD

ABSTRACT 567: A prospective single-arm phase II study of blank-microsphere transarterial chemoembolization (bTACE) plus lenvatinib (LEN) and sequential microwave ablation (MWA) in patients with large hepatocellular carcinoma (L-HCC, ≥ 7 cm): The Talem trial.
First Author: Zhimei Huang

ABSTRACT 568: Anlotinib plus toripalimab as first-line treatment for patients with unresectable hepatocellular carcinoma. Updated results of the ALTER-H003 trial.
First Author: Shuiling Jin

ABSTRACT 569: The impact of relative dose intensity on overall and progression-free survival during cabozantinib therapy for unresectable hepatocellular carcinoma.
First Author: Tsubasa Nobusawa, MD

ABSTRACT 570: ORIENT-32: Updated characterization of response to sintilimab plus bevacizumab biosimilar (IBI305) vs sorafenib for unresectable hepatocellular carcinoma.
First Author: Zhenggang Ren

ABSTRACT 571: A phase II clinical trial to study the use of cabozantinib (cab) in patients with hepatocellular carcinoma (HCC) post immunotherapy treatment.
First Author: Stephen Lam Chan, MD, FRCP

ABSTRACT 572: Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase Ia dose-expansion study.
First Author: Ye Guo, MD

ABSTRACT 573: Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.
First Author: Philippe Merle, MD, PhD

ABSTRACT 574: Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase II study.
First Author: Mingyue Cai, MD, PhD

ABSTRACT 575: Discovery of novel interactions with LCK in cholangiocarcinoma using proximity-dependent biotinylation.
First Author: Jennifer L Tomlinson, MD

ABSTRACT 576: Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
First Author: Shixue Laoguo

ABSTRACT 577: Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Shuiling Jin

ABSTRACT 578: Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.
First Author: Zhenggang Ren

ABSTRACT 579: Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma. A large, real-life, worldwide population.
First Author: Margherita Rimini, MD
POSTER SESSION B, continued

BOARD E12  ABSTRACT 580: Phase II study of cobolimab in combination with dostarlimab for the treatment of advanced hepatocellular carcinoma. First Author: Jared David Acoba, MD

BOARD E13  ABSTRACT 581: Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC). A randomized, controlled, phase II clinical study.
First Author: Hui Zeng

BOARD E14  ABSTRACT 582: Genomic profiling to provide new treatment opportunities in ampullary carcinoma. First Author: Carles Fabregat Franco, MD

First Author: Kehe Chen

BOARD E16  ABSTRACT 584: Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC). First Author: David Hsieh, MD

BOARD E17  ABSTRACT 585: Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab.
First Author: Daneng Li, MD

BOARD E18  ABSTRACT 586: Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis.
First Author: Funda Meric-Bernstam, MD

BOARD E19  ABSTRACT 587: Real-world assessment of treatment sequencing of patients with advanced biliary tract cancer in a private practice in Rio de Janeiro and São Paulo, Brazil.
First Author: Ligia Carvalho

BOARD F1  ABSTRACT 589: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC). First Author: Emil Lou, MD, PhD

BOARD F2  ABSTRACT 590: Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.
First Author: Angela Lamarca, MD

BOARD F3  ABSTRACT 591: Effect of AXL on cholangiocarcinoma survival and sensitivity to cytotoxic chemotherapy.
First Author: Shohei Takaichi, MD, PhD

BOARD F4  ABSTRACT 592: Beyond CPS for PD-L1 scoring: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC).
First Author: Hui Zeng

BOARD F5  ABSTRACT 593: Evaluation of clinical benefit and progression-free survival ratio of targeted treatments in a prospective cohort study of patients with biliary tract cancers.
First Author: Monica Niger, MD

BOARD F6  ABSTRACT 594: Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome.
First Author: Yi Song, MS, MD

BOARD F7  ABSTRACT 595: Correlation of high serum interleukin-6 with clinical outcome and T cell response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
First Author: Hongjae Chon, PhD(c)

BOARD F8  ABSTRACT 596: Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study.
First Author: Claudia A.M. Fulgenzi

BOARD F9  ABSTRACT 597: Artificial intelligence (AI)-powered immune phenotyping to predict outcomes of immuno-oncology (IO)-based regimens in hepatocellular carcinoma (HCC).
First Author: Hongjae Chon, PhD(c)
BOARD F14  ABSTRACT 602: MSI exploration in patients with biliary tract cancer from the Spanish RETUD Registry. First Author: Andrés J. Muñoz Martín Sr., MD, PhD.

BOARD F16  ABSTRACT 604: Concordance in oncogenic alterations between primary and recurrent/metastatic cholangiocarcinoma pairs using targeted next-generation sequencing. First Author: Sarah Margaret Helena McIntyre, MD.

BOARD F17  ABSTRACT 605: Comprehensive molecular profiling in patients with advanced biliary tract cancers (BTC) in a Latinx-rich cohort. First Author: Vidit Kapoor, MD.

BOARD F18  ABSTRACT 606: Integrated analysis of genomic and transcriptomic profiles to examine CD73/NT5E as a driver of drug-resistance and immunosuppression in biliary cancer (BTC). First Author: Pietro Carotenuto.

BOARD F19  ABSTRACT 607: Clinical and mutational profiles of microsatellite instability (MSI-H) in intrahepatic cholangiocarcinoma (iCCA). First Author: Madhulika Eluri, MD.

BOARD F20  ABSTRACT 608: The impact of viral etiology in yttrium-90–treated hepatocellular carcinoma. First Author: So Heun Lee, MD.

BOARD G2  ABSTRACT 609: CD34 immunostaining for microvascular invasion analysis in hepatocellular carcinoma. First Author: Paulo Henrique Costa Diniz, MD.

BOARD G3  ABSTRACT 610: Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results. First Author: Shubham Pant, MD, MBBS.

BOARD G4  ABSTRACT 611: The oncologic implications of tumor multiplicity in intrahepatic cholangiocarcinoma: Its prognostic value might be underestimated. First Author: Bahar Laderian, MD.

BOARD G5  ABSTRACT 612: Three-dimensional radiotherapy dose prediction in patients with liver and pancreas cancer treated with the Viewray system. First Author: Cesar Rodrigo Arce, MD.

BOARD G6  ABSTRACT 613: Serum vitamin D₃ levels and overall survival (OS) in patients (pts) with advanced biliary tract cancer (BTC). Analysis of the NIFTY trial cohort. First Author: Léamarié Mélache-Dumas.


BOARD G8  ABSTRACT 615: A glimpse into the future of hepatocellular carcinoma (HCC): Predicting the future incidence based on the current epidemiological data. First Author: Sri Harsha Tella, MD, FACP.

BOARD G9  ABSTRACT 616: A glimpse into the future of cholangiocarcinoma: Predicting the future incidence based on the current epidemiological data. First Author: Sri Harsha Tella, MD, FACP.

BOARD G10  ABSTRACT 641: Characterizing bone metastases and skeletal-related events in patients with well-differentiated neuroendocrine neoplasms utilizing Ga68-DOTATE PET. First Author: Tucker Coston, MD.

BOARD G11  ABSTRACT 642: Survival outcomes for patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with lutetium-177-dotatate (Lu-177) in a Brazilian reference center. A six-year follow-up experience. First Author: Zenaide Silva Souza.

BOARD G12  ABSTRACT 643: Overall survival (OS) in gastrointestinal (GI) neuroendocrine tumors (NETs) based on primary site, stage, and surgery. First Author: Bahar Laderian, MD.

BOARD G13  ABSTRACT 644: Clinical and radiological response to locoregional and systemic treatments in well-differentiated gastroenteropancreatic neuroendocrine tumors with liver metastases treated at a reference center in Mexico. First Author: Cesar Rodrigo Arce, MD.

BOARD G14  ABSTRACT 645: Evaluating surgical treatment options for small nonfunctional pancreatic neuroendocrine tumors in the NCDB. First Author: Toshitaka Sugawara, MD, PhD.

BOARD G15  ABSTRACT 646: NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC). First Author: Maiiread Geraldine McNamara, PhD, MBBS.

BOARD G16  ABSTRACT 647: Liver-directed therapy of neuroendocrine liver metastases. First Author: Léamarié Mélache-Dumas.
POSTER SESSION B, continued

BOARD G17: ABSTRACT 648: Pharmacokinetics and RP2D analysis from ETCTN 10388: A phase I trial of triapine and lutetium Lu-177 dotatate in well-differentiated somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
   First Author: Aman Chauhan, MBBS

BOARD G18: ABSTRACT 649: Molecular characterization and clinical outcomes of pancreatic neuroendocrine tumors (pNENs) harboring PAK4-NAMPT alterations.
   First Author: Ibrahim Azar, MD

BOARD G19: ABSTRACT 650: Real-world outcomes in patients with gastroenteropancreatic neuroendocrine tumors receiving somatostatin analogue: Data from a public hospital in Brazil.
   First Author: Kaique Ferreira Costa de Almeida

BOARD G20: ABSTRACT 651: Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.
   First Author: Alexandra Androsova, MD

   First Author: Salma Ferosh Usman Khan, MD, MBBS

BOARD H3: ABSTRACT 653: Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in advanced pancreatic neuroendocrine neoplasms (PanNENs).
   First Author: Darren Cowzer, MBCh, MSc

   First Author: Sun Young Jeong, MD

BOARD H5: ABSTRACT 655: Age- and sex-based differences in the genomic profiles of patients with gastrointestinal (GI) and pancreatic neuroendocrine neoplasms (NENs).
   First Author: Lisa Liu

BOARD H6: ABSTRACT 656: The genomic landscape of advanced gastrointestinal (GI) neuroendocrine tumors (NET) and carcinomas (NEC).
   First Author: Nicole Farha, MD

BOARD H7: ABSTRACT 653: Disparities in late-stage pancreatic cancer: Retrospective analysis of genomic testing and outcomes between Hispanics and non-Hispanics.
   First Author: Ricardo J Estrada-Mendizabal, MD

BOARD H8: ABSTRACT 664: Democratizing access to research for patients with pancreatic cancer across a diverse health system through natural language processing of radiology reports.
   First Author: Daniel King, MD, PhD

BOARD H9: ABSTRACT 665: Socioeconomic disparities causing delays in pancreatic cancer germline genetic testing.
   First Author: Xianghui Zou, MD, PhD

BOARD H10: ABSTRACT 666: Rates of unplanned hospital care in Black Americans with pancreatic cancer.
   First Author: Kristen M John, BS

   First Author: Alexander Lim, MD

BOARD H12: ABSTRACT 668: Does distance traveled impact management and outcomes in patients with pancreatic adenocarcinoma who are candidates for curative resection?
   First Author: Mariam Khan, MD

BOARD H13: ABSTRACT 669: Tissue factor (TF) and factor VII/TF ratio (VII:TF) as potential indicators of malignancy in pancreatic cystic lesions.
   First Author: Farzana Haque, MRCP

BOARD H14: ABSTRACT 670: Evolution of pancreatic ductal adenocarcinoma diagnosis during the last decade.
   First Author: Roberto Jiménez Rodríguez, MD

   First Author: Sheeno P. Thyparambil, PhD

BOARD H16: ABSTRACT 672: Early detection of pancreatic cancer using 5-hydroxymethylation profiles in plasma-derived cell-free DNA.
   First Author: Anna Bergamaschi, PhD

BOARD H17: ABSTRACT 673: Adjuvant gemcitabine+S1 as adjuvant therapy for resectable pancreatic cancer: A real-world experience in a single-center retrospective study.
   First Author: Hsin-Chen Lin

BOARD H18: ABSTRACT 674: Clinical implications of peritoneal cytology evaluated by staging laparoscopy for potentially resectable pancreatic cancer.
   First Author: Haruyoshi Tanaka, MD, PhD
BOARD H19 ABSTRACT 675: Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma.
First Author: Jaewoo Kwon

First Author: Christopher Shi

BOARD J2 ABSTRACT 677: Clinical therapeutic effects of neoadjuvant chemotherapy in resectable pancreatic cancer.
First Author: Masaaki Murakawa, MD, PhD

First Author: Yang-Chen Shen

First Author: Jae Hyup Jung, MD

BOARD J5 ABSTRACT 680: Prognostic factors of multidisciplinary treatment for borderline resectable and locally advanced pancreatic adenocarcinoma: Results of a dual-center study.
First Author: Nana Kimura, MD

BOARD J6 ABSTRACT 681: Impact of patient characteristics and treatment patterns on outcomes in potentially resectable pancreatic cancer (PC).
First Author: Andrew Steinmetz

BOARD J7 ABSTRACT 682: Electronic patient-reported outcome measured in patients with pancreatic cancer receiving second-line chemotherapy: A multicenter prospective observational study.
First Author: Akihiro Ohba, MD

First Author: Marytere Herrera, MD

BOARD J9 ABSTRACT 684: Real-world impact of initial treatment modality on survival outcomes in patients with stage I-III pancreatic ductal adenocarcinoma.
First Author: Ajay Prakash, MD, PhD

BOARD J10 ABSTRACT 685: Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).
First Author: Fergus Keane, MBChB, MA

First Author: Jackeline Macetas, MD

BOARD J12 ABSTRACT 687: Racial, ethnic, and sex-based disparities among high-risk individuals undergoing pancreatic cancer surveillance.
First Author: Kelsey Klute, MD

BOARD J13 ABSTRACT 688: Guideline compliance and outcomes of genetic testing in pancreatic cancer patients.
First Author: Derk C.F. Klatte, MD

BOARD J14 ABSTRACT 689: Pancreatic imaging findings from the PRECEDE study: A large high-risk heritable cohort for pancreatic cancer.
First Author: Ido Haimi, MD

BOARD J15 ABSTRACT 690: Comparison of pancreatic cancer outcomes diagnosed in surveillance and the general population: A propensity score-matched analysis.
First Author: Derk C.F. Klatte, MD

BOARD J16 ABSTRACT 691: Prospective characterization of oral and gut microbiome in a high-risk pancreatic cancer cohort.
First Author: Seyda Baydogan, MD

BOARD J17 ABSTRACT 692: Analysis of the treatment outcome of ampulla of Vater carcinoma and the usefulness of postoperative adjuvant chemotherapy.
First Author: Shinichiro Ogawa

BOARD J18 ABSTRACT 693: Association of CA19-9 and tumor size in treatment monitoring for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Andrew Hahn, B.A.

BOARD K1 ABSTRACT 694: Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial.
First Author: Sina Buchholz

BOARD K2 ABSTRACT 695: Effect of neoadjuvant therapy pathway (NATP) for pancreatic cancer on overall patient outcomes.
First Author: Dylan Cooper

BOARD K3 ABSTRACT 696: Patterns of pancreatic enzyme replacement therapy (PERT) use among U.S. patients with pancreatic cancer.
First Author: Trang Quynh Dang
POSTER SESSION B, continued

First Author: Giulia Orsi, MD

BOARD K5: ABSTRACT 698: Effect of pancreatic enzyme replacement therapy (PERT) on body weight in advanced pancreatic cancer (APC).
First Author: Vincent J. Picozzi, MD, MMM

BOARD K6: ABSTRACT 699: The association of the CARE Frailty Index with survival among older adults with pancreatic cancer.
First Author: Vinod Kumar, MD, FACP, MS

BOARD K7: ABSTRACT 700: Assessment of an emergency 14-day (d) integrative supportive care program (14-EISCP) followed by early chemotherapy (CTx) in symptomatic patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): A prospective ARCAD cohort study.
First Author: Benoit Rousseau, MD, PhD

First Author: Davide Melisi, MD, PhD

First Author: Trudy Wu, MD

BOARD K10: ABSTRACT 703: Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer.
First Author: Bo Shen, MD

First Author: Douglas Dias e Silva

BOARD K12: ABSTRACT 705: Efficacy and safety of nanoliposomal irinotecan plus fluorouracil and folinic acid after irinotecan-based chemotherapy in patients with advanced pancreatic cancer: Results of the retrospective part of the NAPOLEON-2 study.
First Author: Yasunori Kawaguchi, MD, PhD

First Author: Takashi Imajima, MD

First Author: Naohiro Okano, PhD, MD

First Author: Andrew L. Coveler, MD

BOARD K16: ABSTRACT 709: Phase I study of proton therapy in adjuvant pancreatic cancer (PROTON-PANC).
First Author: Benjamin Adam Weinberg, MD

BOARD K17: ABSTRACT 710: Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer.
First Author: Marsha Reyngold, MD, PhD

First Author: Bomi Kim, MD

BOARD K19: ABSTRACT 712: Exploring optimal therapeutic management of STAGE IA PDAC in the era of neoadjuvant chemotherapy.
First Author: Marina Macchini, MD, PhD

First Author: Karyn A. Goodman, MD

BOARD L1: ABSTRACT 714: Incidence and clinical characteristics of patients with LAPC and mesenteric vein thrombosis and current treatment paradigm.
First Author: Amer H. Zureikat, MD, FACS

First Author: Choong-kun Lee, MD, PhD
ABSTRACT 716: Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma. First Author: Michele Reni, MD

ABSTRACT 718: Surgical outcomes after neoadjuvant ablative dose radiation among patients with borderline resectable and locally advanced pancreas cancer from the multi-institutional phase 2 Stereotactic MR-Guided Adaptive Radiation Therapy (SMART) trial. First Author: Parag Parikh, MD

ABSTRACT 719: A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). First Author: Theodore S. Hong, MD

ABSTRACT 720: Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1-NK cell therapy. First Author: Tara Elisabeth Seery, MD

ABSTRACT 721: Prediction of early treatment failure of second-line nal-iri/5-FU/FA in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). First Author: Meinolf Karthaus, MD

ABSTRACT 722: Multiagent neoadjuvant chemotherapy compared to upfront surgery in pancreatic cancer of the body and tail using the National Cancer Database. First Author: Oskar Franklin, MD, PhD

ABSTRACT 723: Effects of losartan and vitamin D on outcomes in metastatic pancreatic adenocarcinoma. First Author: Adam Adika, MD

ABSTRACT 724: Efficacy of sequential perioperative FOLFIRINOX plus gemcitabine nab-paclitaxel for resected pancreatic and periampullary cancers. First Author: Putao Cen, MD

ABSTRACT 725: A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC). First Author: Fergus Keane, MBChB, MA

ABSTRACT 726: Using tumor growth rate to inform treatment efficacy in pancreatic adenocarcinoma: From the metastatic to the neoadjuvant setting. First Author: Meredith LaRose, MD

ABSTRACT 727: Irreversible electroporation as treatment option within a multidisciplinary approach for locally advanced pancreatic cancer. First Author: Ansley Beth Ricker, MD

ABSTRACT 728: Intra-arterial gemcitabine vs IV gemcitabine PK substudy in patients with locally advanced pancreatic cancer. First Author: Amer H. Zureikat, MD, FACS

ABSTRACT 729: Pressure-Enabled Drug Delivery™ (PEDD™) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model. First Author: Benedict Capacio, MD

ABSTRACT 730: Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study. First Author: Eric Christensen, MD

ABSTRACT 731: Phase I study of trifluridine/tipiracil in combination with gemcitabine (gem) and nab-paclitaxel (nab-P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC). First Author: Anita Ahmed Turk, MD, BA

ABSTRACT 732: Effects of gene expression in 5-FU metabolic pathways in a phase III trial evaluating adjuvant S-1 therapy compared to surgery alone following curative resection for biliary tract cancer. First Author: Shuichi Mitsunaga, MD

ABSTRACT 733: Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN. First Author: Shun Tezuka, MD, PhD

ABSTRACT 734: The identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib. First Author: Timothy J Brown, MD

ABSTRACT 735: Prognostic indicators of KRAS G12X mutations in pancreatic cancer. First Author: Bach Ardalan, MD

ABSTRACT 736: The divergent role of the GM-CSF/GM-CSFR signaling pathway in cholangiocarcinoma and pancreatic ductal adenocarcinoma. First Author: Yatee A. Dave, MD
ABSTRACT 737: Analysis of plasma circulating tumor DNA in borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant modified FOLFIRINOX: Clinical relevance of DNA damage repair gene alterations.
First Author: Dong-Hoon Lim

First Author: Emma G. Sturgill, PhD

ABSTRACT 739: A pilot study for single cell RNA-sequencing of patient-derived pancreatobiliary cancer organoid.
First Author: Bomi Kim, MD

ABSTRACT 740: Relationship between inflammatory indexes and Khorana score (KS) with prognosis and survival in pancreatic ductal adenocarcinoma (PDAC).
First Author: Rocío Martín Lozano, MD

ABSTRACT 741: Genomic profiling of rare undifferentiated sarcomatoid subtypes of pancreatic carcinomas for potential response to immunotherapy.
First Author: Erik Faber, PhD

ABSTRACT 742: Feasibility of implantable microdosing devices to perform in vivo pharmacotyping in pancreatic cancer.
First Author: Lyudmyla Demyan, MD

First Author: Viswesh Krishna

ABSTRACT 744: Patient-specific tumor-informed circulating tumor DNA (ctDNA) assay to predict cancer recurrence in patients with resected pancreatic cancer.
First Author: Xiuchao Wang

ABSTRACT 745: Clinical significance of CA125 in unresectable pancreatic cancer treated with first-line chemotherapy.
First Author: Iori Motoo, MD, PhD

First Author: Taro Shibuki, MD

ABSTRACT 747: Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.
First Author: Brendon Fusco, MD

ABSTRACT 748: The role of Smad4/TGFβ signaling in tumorigenesis of pancreatic ductal adenocarcinoma (PDAC).
First Author: Hannah Yoo

ABSTRACT 749: Impact of KRAS mutation variants on clinicopathological features and outcomes in patients with metastatic pancreatic adenocarcinoma.
First Author: Chirag Patel, MD

ABSTRACT 750: KRAS WT pancreatic adenocarcinomas: Another disease?
First Author: Imen BEN-AMMAR

ABSTRACT 751: The Endoscopic Ultrasound Molecular Analysis of Pancreatic Cancer (EUMEPC) study.
First Author: Joanne Lundy, PhD, FRACP, MBBS

ABSTRACT 752: The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line.
First Author: Andrea Pretta, MD

ABSTRACT 753: The utility of PD-L1 as a prognostic marker in pancreatic ductal adenocarcinoma (PDAC).
First Author: Linda Wu, MD

ABSTRACT 754: ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma.
First Author: Maahum Mehdi, BS

First Author: Oluseyi Abidoye

ABSTRACT 756: Quality of educational YouTube videos related to pancreatic cancer: Analysis of patient-focused and NCI-designated cancer center videos.
First Author: Alexander Didier

ABSTRACT 757: Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Jaclyn P. Lyman, MSc
ABSTRACT 783: Treatment sequencing for patients with localized duodenal and ampullary adenocarcinoma.
First Author: Abhishek Janardan, BA
Friday, January 20

12:00 PM - 1:30 PM and 4:30 PM - 5:30 PM
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
LEVEL 1, WEST HALL

Posters by Topic
Diagnostics (Hepatobiliary Cancer): N6
Patient-Reported Outcomes and Real-World Evidence (Hepatobiliary Cancer): N7
Therapeutics (Hepatobiliary Cancer): N8, N9, N10, N11, N12, N13, N14, N15, N16, N17, N18, N19, N20, P1, P2, P3, P4, P5, P6, P7, P8, P9
Therapeutics (Neuroendocrine/Carcinoid): P10, P11
Translational Research (Neuroendocrine/Carcinoid): P12
Tumor Biology, Biomarkers, and Pathology (Neuroendocrine/Carcinoid): P13
Prevention, Screening, and Hereditary Cancers (Pancreatic Cancer): P14
Therapeutics (Pancreatic Cancer): P15, P16, P17, P18, P19, P20, Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q10, Q11, Q12, Q13, Q14, Q15, Q16
Translational Research (Pancreatic Cancer): Q17
Other (Pancreatic Cancer): Q18
Therapeutics (Small Bowel Cancer): Q19

First Author: Dhruvajyoti Roy, PhD

BOARD N7 ABSTRACT TPS618: Real-world registry of patients with unresectable hepatocellular carcinoma: The OREIOS study.
First Author: Stephen Lam Chan, MD, FRCP

BOARD N8 ABSTRACT TPS619: A single-arm, open-label, phase II study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.
First Author: Xiaofeng Chen, Pro.

First Author: Shishir K. Maithel, FACS

BOARD N10 ABSTRACT TPS621: Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT).
First Author: Satoshi Nara, MD

First Author: Aiwu Ruth He, MD, PhD

BOARD N12 ABSTRACT TPS623: An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
First Author: Tanios S. Bekaii-Saab, MD

BOARD N13 ABSTRACT TPS624: A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
First Author: Changqing Xie, MD, PhD

BOARD N14 ABSTRACT TPS625: A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
First Author: Brian Hemendra Ramnaraigh, MD

BOARD N15 ABSTRACT TPS626: A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
First Author: Timothy J. Brown, MD

BOARD N16 ABSTRACT TPS627: A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).
First Author: Ildefonso Ismael Rodriguez Rivera, MD

BOARD N17 ABSTRACT TPS628: An open-label, multi-center phase IIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).
First Author: Jia Fan, MD, PhD

BOARD N18 ABSTRACT TPS629: A phase II study of atezolizumab (ATEZCO) and bevacizumab (BEV) in combination with Y90 TARE in patients (pts) with hepatocellular carcinoma (HCC): Y90+/- BEAT.
First Author: Renuka V. Iyer, MD
BOARD N19  ABSTRACT TPS630: Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.
First Author: Lucia Andemicael

BOARD N20  ABSTRACT TPS631: A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
First Author: T.R. Jeffry Evans, MD, MBBS, FRCP

BOARD P1  ABSTRACT TPS632: ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
First Author: Xianhai Mao

BOARD P2  ABSTRACT TPS633: A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BiGenCap Study): KCSG-HB20-14.
First Author: Joon Oh Park, MD, PhD

BOARD P3  ABSTRACT TPS634: Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
First Author: Jaekyung Cheon, MD

BOARD P4  ABSTRACT TPS635: A phase II trial of hyperthermic intraperitoneal chemotherapy combined with tislelizumab and targeted therapy in high-risk hepatocellular carcinoma after R0 resection.
First Author: Sulai Liu

BOARD P5  ABSTRACT TPS636: RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC).
First Author: Bruno Sangro, MD, PhD

BOARD P6  ABSTRACT TPS637: First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRI), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
First Author: James J. Harding, MD

BOARD P7  ABSTRACT TPS638: Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant.
First Author: Davendra Sohal, MD, MPH

BOARD P8  ABSTRACT TPS639: ECTN 10476: A randomized phase 2 study of combination atezolizumab and varilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.
First Author: Thatcher Ross Heumann, MD, MPH

BOARD P9  ABSTRACT TPS640: Trial in progress: A phase 2/3 randomized, controlled study of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen.
First Author: Marilyn Fontaine, BSc

BOARD P10  ABSTRACT TPS657: Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFN-β-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma.
First Author: Patrick Walsh McGarrah, MD

BOARD P11  ABSTRACT TPS658: ECTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan, MBBS

BOARD P12  ABSTRACT TPS659: Natural history study and tissue procurement of neuroendocrine neoplasms (NENs).
First Author: Rosa Mallorson

BOARD P13  ABSTRACT TPS660: Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.
First Author: Thorvardur Ragnar Halfdanarson, MD

BOARD P14  ABSTRACT TPS758: A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer.
First Author: Saurav Daniel Haldar, MD

BOARD P15  ABSTRACT TPS759: A pilot study of gut microbiome modulation to enable efficacy of neoadjuvant checkpoint-based immunotherapy (IO) following chemotherapy in pancreatic ductal adenocarcinoma (PDAC).
First Author: Linda Wu, MD

BOARD P16  ABSTRACT TPS760: A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma.
First Author: Mandana Kamgar, MD, MPH
TRIALS IN PROGRESS POSTER SESSION B, continued

BOARD P17 
ABSTRACT TPS761: Phase II study (daNIS-1) of the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai, MD

BOARD P18 
ABSTRACT TPS762: Phase Ib study testing neoadjuvant transforming growth factor (TGF)-β antibody, NIS793, plus 5-fluorouracil, irinotecan, and oxaliplatin chemotherapy (FOLFIRINOX) in patients (pts) with borderline resectable (BR)/locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).
First Author: Colin D. Weekes, MD, PhD, FASCO

BOARD P19 
ABSTRACT TPS763: APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192.
First Author: Kim Anna Reiss, MD

BOARD P20 
ABSTRACT TPS764: Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.
First Author: Anthony W. Tolcher, MD, FASCO

BOARD Q1 
ABSTRACT TPS765: Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Zev A. Wainberg, MD

BOARD Q2 
ABSTRACT TPS766: Greco-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer.
First Author: Todd Anthony Aguilera, MD, PhD

BOARD Q3 
ABSTRACT TPS767: A phase I dose escalation study of carbon-ion radiotherapy for pancreatic cancer.
First Author: Makoto Shinoto, MD, PhD

BOARD Q4 
ABSTRACT TPS768: A phase Ib study testing the anti–TGF-β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Li-Yuan Bai, MD

BOARD Q5 
First Author: Joon Oh Park, MD, PhD

BOARD Q6 
ABSTRACT TPS770: Tumor treating fields (TTFields) concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer: The phase 3 PANOVA-3 study.
First Author: Vincent J. Picozzi, MD, MMM

BOARD Q7 
ABSTRACT TPS771: An adaptive approach to neoadjuvant therapy to maximize resection rates for pancreatic adenocarcinoma: A phase II trial.
First Author: Davendra Sohal, MD, MPH

BOARD Q8 
ABSTRACT TPS772: Casper: A phase I, open-label, dose finding study of calaspargase pegol-mnkl (cala) in combination with cobimetinib (cobi) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez, PhD, MD

BOARD Q9 
ABSTRACT TPS773: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TiGer-PaC): A randomized phase 3 multicenter study.
First Author: Michael J. Pishvaian, MD, PhD

BOARD Q10 
ABSTRACT TPS774: The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation.
First Author: Arnold Glazier, MD

BOARD Q11 
ABSTRACT TPS775: Phase I study of PTM-101 as neoadjuvant therapy for borderline resectable or locally advanced pancreatic ductal adenocarcinoma: A trial in progress.
First Author: Charles Pilgrim, PhD, MBBS

BOARD Q12 
ABSTRACT TPS776: Updates to NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez, PhD, MD
BOARD Q13  ABSTRACT TPS777: Sonoporation for disrupting the pancreatic cancer microenvironment to enhance chemotherapy delivery and improve outcomes. First Author: James Posey, MD

BOARD Q14  ABSTRACT TPS778: A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study). First Author: Sherise C. Rogers, MD, MPH

BOARD Q15  ABSTRACT TPS779: Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR TMSLN) in patients with metastatic pancreatic ductal adenocarcinoma (mPDA). First Author: E. Gabriela Chiorean, MD

BOARD Q16  ABSTRACT TPS780: Trial in progress: Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer. First Author: Robert R. McWilliams, MD

BOARD Q17  ABSTRACT TPS781: A window of opportunity trial for metastatic (WOO-M) pancreatic ductal adenocarcinoma (PDAC): A biomarker discovery platform. First Author: Charles D. Lopez, PhD, MD

BOARD Q18  ABSTRACT TPS782: Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study. First Author: Wungki Park, MD

BOARD Q19  ABSTRACT TPS784: Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922. First Author: Michael J. Overman, MD
Saturday, January 21

6:30 AM - 7:55 AM and 12:30 PM - 2:00 PM
Poster Session C: Cancers of the Colon, Rectum, and Anus
LEVEL 1, WEST HALL

Posters by Topic
Diagnostics (Anal Cancer): A6
Tumor Biology, Biomarkers, and Pathology (Anal Cancer): A7
Cancer Disparities (Colorectal Cancer): A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18
Diagnostics (Colorectal Cancer): A19, A20, B1, B2, B3, B4, B5, B6
Impact of COVID-19 (Colorectal Cancer): B7, B8
Patient-Reported Outcomes and Real-World Evidence (Colorectal Cancer): B9, B10, B11, B12, B13, B14, B15, B16, B17, B18, B19, B20, C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, D1, D2, D3, D4
Prevention, Screening, and Hereditary Cancers (Colorectal Cancer): D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18
Quality of Care/Quality Improvement (Colorectal Cancer): A5, D19, D20, E1, E2, E3
Symptoms, Toxicities, and Whole-Person Care (Colorectal Cancer): E4, E5, E6, E7, E8, E9, E10, E11, E12
Translational Research (Colorectal Cancer): J7, J8, J9, J10, J11, J12, J13, J14, J15, J16, J17, J18, K1, K2, K3, K4, K5, K6, K7, K8, K9, K10, K11, K12, K13, K14, K15
Tumor Biology, Biomarkers, and Pathology (Colorectal Cancer): A4, K16, K17, K18, K19, K20, L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14, L15, L16, L17, L18, L19, L20, M1, M2, M3, M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14, M15, M16, M17, M18, M19, M20, N1, N2, N3, N4, N5, N6, N7, N8, N9, N10, N11, N12, N13, N14
Other (Colorectal Cancer): N15, N16, N17, N18

BOARD A1 ABSTRACT LBA8: Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). First Author: Anthony B. El-Khoueiry, MD

BOARD A2 ABSTRACT 132: Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial. First Author: Qi Lin, MD

BOARD A3 ABSTRACT 10: Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. First Author: Paul Bernard Romesser, MD

BOARD A4 ABSTRACT 11: Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. First Author: Kohei Shitara, MD

BOARD A5 ABSTRACT 12: A double-blind, randomized, placebo-controlled, parallel study to investigate the auxiliary effects of fucoidan in patients with locally advanced rectal cancer who receive neoadjuvant concurrent chemoradiotherapy before surgery. First Author: Jaw-Yuan Wang, MD, PhD

BOARD A6 ABSTRACT 2: Concordance of genomic alterations in anal cancer by next-generation sequencing in tissue and circulating tumor DNA. First Author: Michael Brian LaPelusa, MD

BOARD A7 ABSTRACT 3: Survival benefit to immunotherapy according to site of organ involvement in metastatic anal cancer. First Author: Arjun S. Peddireddy

BOARD A8 ABSTRACT 13: Racial disparities in tumor microbiome in young-onset and average-onset colorectal cancer. First Author: Heloni M Dave, MBBS

BOARD A9 ABSTRACT 14: Racial and regional disparities in the management of locally advanced rectal cancer. First Author: William Yu Luo, MD, BS

BOARD A10 ABSTRACT 15: Impact of COVID-19 pandemic on diagnosis, staging, and outcomes of patients with early-onset colorectal cancer. First Author: Daniel Martinez-Perez

BOARD A11 ABSTRACT 16: Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer. First Author: Riya Jayesh Patel, MD

BOARD A12 ABSTRACT 17: Clinical outcomes and barriers to cancer care delivery for patients with rectal cancer in Nairobi, Kenya. First Author: Dulcie Wanda

BOARD A13 ABSTRACT 18: Disparities in colorectal cancer: Trends of reduced screening among minority populations. First Author: Ahmed Ouni
ABSTRACT 19: Racial/ethnic differences of germline pathogenic variants in cancer susceptibility genes among patients with early-onset colorectal cancer.
First Author: Andreana N. Holowatyj, PhD

ABSTRACT 20: Comparison of treatment utilization and clinical outcomes among elderly patients with colon cancer from a limited-resource and high-resource setting.
First Author: Joanna El Hajj, MD

ABSTRACT 21: Disparate outcomes for Black patients following neoadjuvant chemoradiation for rectal cancer are multifactorial in origin.
First Author: Rebecca Maria Shulman, MD

ABSTRACT 22: Clinical outcomes and healthcare utilization among young adults with colon cancer on Medicaid vs private insurance.
First Author: Vaishali Deenadayalan, MD

ABSTRACT 23: Source of funding and enrollment disparities in the inclusion of minorities in colorectal clinical trials: A systematic review and meta-analysis.
First Author: Ahsan Ayaz, MBBS

ABSTRACT 24: Deep learning–assisted colonoscopy images for prediction of mismatch repair deficiency in colorectal cancer.
First Author: Jiancong Hu

ABSTRACT 25: Genomic analysis to elucidate similarities and differences between primary colorectal cancers and colorectal cancer liver metastases.
First Author: Steven Allen Buechler, PhD

ABSTRACT 26: A multicenter, case-control study of a novel multi-target fecal DNA test for colorectal cancer detection.
First Author: Jiaxi Peng, PhD

ABSTRACT 27: Identifying targeted therapy combination for refractory colorectal cancer using micro-organospheres.
First Author: Shengli Ding, PhD

ABSTRACT 28: Plasma-only multiomic minimal residual disease (MRD) testing in 2,000 consecutive patients with colorectal cancer (CRC).
First Author: Katrina Sophia Pedersen, MD, MS

ABSTRACT 29: Survival and clinical characteristics of patients with colorectal cancer and brain metastases.
First Author: Caroline Gordon, MD

ABSTRACT 30: Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in >28,000 colorectal tumors.
First Author: Rouba Ali-Fehmi

ABSTRACT 31: A single center survival analysis of patients with colorectal cancer who underwent next generation sequencing.
First Author: Lucyna Krzywon

First Author: Mitsukuni Suenaga, PhD, MD

First Author: Rozanne Wilson, PhD

ABSTRACT 34: Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study.
First Author: Sebastian Stintzing, MD

ABSTRACT 35: Exploring demographic differences and outcomes in young-onset colorectal cancer.
First Author: Deepak Vadehra, DO

ABSTRACT 36: Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer (mCRC).
First Author: Tsung-Che Wu, MD

ABSTRACT 37: Relevance of adjuvant chemotherapy in elderly patients with low rectal tumors.
First Author: Sola Adeleke, MBBS, PhD

ABSTRACT 38: Emergence of RAS mutations in RAS wild type metastatic colorectal cancer patients receiving cetuximab as first-line treatment: A prospective study.
First Author: Hsiang-Lin Tsai, MD, PhD, CRC

First Author: Nadina Tinsley, MBBS, MRCP

ABSTRACT 40: Real-world survival of patients (pts) with colorectal adenocarcinoma liver metastases (CRLM) treated with transarterial radioembolization (TARE).
First Author: Sharmeen Mahmood, DO
POSTER SESSION C, continued

BOARD B16  ABSTRACT 41: Real-world clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS G12C–mutated metastatic colorectal cancer in AACR Project GENIE.
First Author: Hil Hsu, PhD, MPH

BOARD B17  ABSTRACT 42: First-line anti-EGFR or anti-VEGF therapy, tumour sidedness, and survival: Results from the South Australian (SA) Metastatic Colorectal Cancer (mCRC) Registry.
First Author: Tharani Krishnan, MBBS

BOARD B18  ABSTRACT 43: Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.
First Author: Kruti Bhagirath Vora, MD

BOARD B19  ABSTRACT 44: Real-world effectiveness and safety of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: A retrospective observational study using an administrative database.
First Author: Eiji Shinozaki, MD, PhD

BOARD B20  ABSTRACT 45: Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study.
First Author: Carlo Signorelli, MD

BOARD C1  ABSTRACT 46: Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC).
First Author: Haley Ellis, MD

BOARD C2  ABSTRACT 47: The role of primary tumor resection in synchronous stage IV colorectal cancer: Subgroup analysis.
First Author: Hojung An, MD, PhD

First Author: Gong Chen, MD, PhD

BOARD C4  ABSTRACT 49: Impact of high-dose dexamethasone and prolonged infusion time to prevent hypersensitivity reaction related to oxaliplatin in patients with colorectal cancer.
First Author: Koichiro Yoshino

BOARD C5  ABSTRACT 50: Clinical outcomes of appendix goblet cell adenocarcinoma and role of systemic chemotherapy.
First Author: Madeleine Cornelia Strach, FRACP, MBBS, MPH

BOARD C6  ABSTRACT 51: Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212).
First Author: Alexej Ballhausen, MD

BOARD C7  ABSTRACT 52: Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).
First Author: Samuel J Klemmner, MD

BOARD C8  ABSTRACT 53: Burden of illness in metastatic colorectal cancer.
First Author: Edward Neuberger, PharmD, MBA

BOARD C9  ABSTRACT 54: The efficacy of capecitabine as a salvage treatment in metastatic colorectal cancer after prior 5-fluorouracil–included chemotherapies.
First Author: Jae Yeon Jang, MD

First Author: Mariana Gil, MD

BOARD C11  ABSTRACT 56: Real-world use of biologics and its association with outcomes in RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) in Canada.
First Author: Winson Y. Cheung, MD, MPH

First Author: Bahar Saberzadeh Ardestani, MD, MPH

BOARD C13  ABSTRACT 58: Impact of complete pathological response outcome in Latin American patients with rectal cancer.
First Author: German Calderillo-Ruiz, MD

BOARD C14  ABSTRACT 59: Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer.
First Author: Chengwei Peng, MD

BOARD C15  ABSTRACT 60: Psychosocial, behavioral, and communication factors associated with completion of the mt-sDNA test for colorectal cancer screening.
First Author: Shama Alam, PhD

BOARD C16  ABSTRACT 61: Association of awareness and use of patient navigation services for colorectal cancer screening with test completion and likelihood of future use.
First Author: Shama Alam, PhD
BOARD C17  ABSTRACT 62: Total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A real-world experience. First Author: Erika Ruiz-Garcia, MD, MS

BOARD C18  ABSTRACT 63: Quality-of-life outcomes after total neoadjuvant short course radiotherapy, chemo-immunotherapy, and total mesorectal excision for locally advanced rectal cancer. First Author: Ali Shamseddine, MD, FRCP

BOARD D1  ABSTRACT 64: Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC). An age-stratified analysis. First Author: Zdravko Vassilev, MD, MPH

BOARD D2  ABSTRACT 65: Clinical outcomes in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in the pre-immunotherapy era. First Author: Koen Zwart, MD

BOARD D3  ABSTRACT 66: Clinical and survival characteristics of patients with BRAF-mutated metastatic colorectal cancer (mCRC) who receive metastases surgery in a Spanish cohort. First Author: Javier Soto Sr., MD

BOARD D4  ABSTRACT 67: Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study. First Author: Alberto F. Sobrero, MD

BOARD D5  ABSTRACT 68: Adult BMI change over time and risk of colorectal adenoma. First Author: Parker Holum

BOARD D6  ABSTRACT 69: Use of glycoproteome profiles to detect advanced adenomas and colorectal cancer. First Author: Khushbu Desai, MS

BOARD D7  ABSTRACT 70: Calculator for detection of colorectal adenomas by using artificial intelligence models in patients with chronic hepatitis C. First Author: Maya Gogtay, MD

BOARD D8  ABSTRACT 71: Screening or symptoms? Colorectal cancer diagnosis in Uruguay. First Author: Santiago Fontes, MD, MSc

BOARD D9  ABSTRACT 72: Internet-based assessment tools for predicting colorectal cancer risk: How do they communicate individualized risk to the young adult? First Author: Allison Janak, BS

BOARD D10  ABSTRACT 73: Cost effectiveness of liquid biopsy for colorectal cancer screening. First Author: Zainab Aziz

BOARD D11  ABSTRACT 74: Comparison of precursor neoplasms at colonoscopic diagnosis of early-onset and later-onset colon cancer. First Author: Oluwadunni Eunice Emiloju, MD, MSc

BOARD D12  ABSTRACT 75: Clinical performance of a multimodal screening blood test for advanced adenomas and CRC in an average-risk cohort of 1,038 participants. First Author: Shai Friedland, MD

BOARD D13  ABSTRACT 76: Metachronous colorectal cancers in Icelandic MSH6 and PMS2 Lynch syndrome carriers in 1955-2017: A population-based study. First Author: Sigurdis Haraldsdottir, MD, PhD

BOARD D14  ABSTRACT 77: Next-generation whole blood transcriptome-based assay for advanced adenoma detection. First Author: Sahar Hosseinian Ehrensberger

BOARD D15  ABSTRACT 78: Spectrum of germline mutations among Mexican patients with colorectal cancer. First Author: Dione Aguilar, MD

BOARD D16  ABSTRACT 79: The inequity in emergency room utilization prior to colorectal cancer diagnosis and the opportunity to improve access to colorectal cancer screening. First Author: Afsaneh Barzi, MD, PhD

BOARD D17  ABSTRACT 80: Association of lifestyle-related risk factors with incidence and mortality rates of colorectal cancer among adolescents and young adults (AYA) in the United States. First Author: Udhayvir Singh Grewal, MD

BOARD D18  ABSTRACT 81: Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk. First Author: Erika Leigh Spaeth Tuff, PhD

BOARD D19  ABSTRACT 82: Diagnostics and treatment for HER2+ mG&CRC: Learning outcomes of GetSMART. First Author: Emil Lou, MD, PhD

BOARD D20  ABSTRACT 83: Costs of adverse event management associated with first-line cetuximab or panitumumab in patients with metastatic colorectal cancer in Spain. First Author: Begoña Graña Suárez, MD, PhD

BOARD E1  ABSTRACT 84: SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors. First Author: Michael Jefford, PhD, MPH, MBBS
First Author: Jacob Beck Leary, MD

ABSTRACT 86: Reflex testing for RAS and BRAF mutations in metastatic colorectal cancer: A single Canadian academic oncology center experience.
First Author: Lena Cvetkovic, MD

ABSTRACT 87: The mortality burden of cachexia in patients with colorectal or pancreatic cancer: A systematic literature review.
First Author: Richard Francis Dunne, MD

ABSTRACT 88: Symptom burden over time among early-onset young adult colorectal cancer survivors.
First Author: Justin Cheng, BA

ABSTRACT 89: Severe enterocolitis with capecitabine (CAPE) is not a predictor of gastrointestinal (GI) toxicity with infusional 5-fluorouracil (5-FU)–based regimens: An institutional analysis.
First Author: Marie Parish, PharmD, BCOP

ABSTRACT 90: Radiation exposure from diagnostic CT for young patients with colon cancer in the first 5 years after diagnosis.
First Author: Melissa Amy Lumish, MD

ABSTRACT 91: Toxicities and outcomes of neoadjuvant treatment in elderly patients with locally advanced rectal cancer: A scoping review.
First Author: Ruba Ahmed Mohammed Hamed, MBBS

ABSTRACT 92: LEANOX: Lean body mass normalization of oxaliplatin-based chemotherapy for patients with stage III colon cancer treated in adjuvant setting: Impact on oxaliplatin-induced sensitive neurotoxicity—A multicenter phase II randomized trial.
First Author: Eric Assenat, MD, PhD

ABSTRACT 93: BXQ-350 may alleviate symptoms of chemotherapy-induced peripheral neuropathy via modulation of S1P.
First Author: Robert Wesolowski, MD

First Author: Daniel Martinez-Perez

ABSTRACT 95: Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
First Author: Christopher G. Cann, MD

ABSTRACT 96: One-week versus two-week chemoradiotherapy followed by curative surgery in rectal cancer: Long-term comparative pooled analysis of two prospective multicenter phase II trials.
First Author: Jong Hoon Lee, MD

ABSTRACT 97: Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRo-001 + irinotecan vs. regorafenib + irinotecan in third/fourth-line colorectal cancer.
First Author: Tony R. Reid, MD, PhD

ABSTRACT 98: Phase 1 dose-finding trial of cabozantinib (cabo) and trifluridine/tipiracil (FTD/TPI) in metastatic colorectal carcinoma (mCRC).
First Author: Farshid Dayyani, PhD

ABSTRACT 99: Effect of Tabernero’s prognostic subgroups or development of neutropenia on survival outcomes of patients with refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil plus bevacizumab (TASBEV) in real-world practice.
First Author: Nieves P. Martinez-Lago, MD PhD

ABSTRACT 100: Phase III FIRE-4 study (AIO KRK-0114): Evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC receiving the first cycle of treatment with chemotherapy only.
First Author: Sebastian Stintzing, MD

ABSTRACT 101: Phase 2 multi-institutional prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged 80 years or more after curative resection of colorectal cancer: The HiSCO-03 study.
First Author: Masashi Miguchi Sr., MD, PhD

ABSTRACT 102: Prospective cohort study of patients with stage III colorectal cancer aged ≥ 80 years who underwent curative resection: The HiSCO-04 study.
First Author: Manabu Shimomura Sr., MD, PhD

ABSTRACT 103: HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer—Preliminary efficacy and correlative results.
First Author: Kristen Renee Spencer, MPH, DO
BOARD F1  ABSTRACT 104: Bleeding and thrombotic events in patients with colorectal cancer treated with bevacizumab and receiving novel oral anticoagulants and antiplatelet medications.  
First Author: Shinji Rho

BOARD F2  ABSTRACT 105: The efficacy and safety of neoadjuvant immunotherapy in patients with deficient mismatch repair/microsatellite instability–high (dMMR/MSI-H) localized and oligometastatic colon cancer. Data from the real world.  
First Author: Sakti Chakrabarti, MD

BOARD F3  ABSTRACT 106: A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.  
First Author: Shunsuke Kondo, MD, PhD

BOARD F4  ABSTRACT 107: Comparative study of prognosis of conversion therapy vs palliative therapy without surgery in colorectal cancer with synchronous liver metastasis according to risk classifications.  
First Author: Hiroaki Nozawa, PhD

BOARD F5  ABSTRACT 108: Survival outcomes and functional results of VOLTAGE-A: Preoperative chemoradiation therapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability–high (MSI-H) locally advanced rectal cancer (LARC).  
First Author: Yuichiro Tsukada, MD, PhD

BOARD F6  ABSTRACT 109: A phase II study of CAPDXIRI as a neoadjuvant chemotherapy in patients with locally advanced rectal cancer (Colorectal Cancer Treatment Group, MSCSG).  
First Author: Yoshinori Kagawa, MD

BOARD F7  ABSTRACT 110: Regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy-resistant MSS metastatic colorectal cancer (mCRC).  
First Author: Marwan Fakih, MD

BOARD F8  ABSTRACT 111: A phase 1b study of navicixizumab plus FOLFIRI in second-line treatment of patients with metastatic colorectal cancer.  
First Author: Kian-Huat Lim, MD, PhD

BOARD F9  ABSTRACT 112: Efficacy of adjuvant fluoropyrimidine with or without oxaliplatin therapy in older adults with mismatch repair deficient stage III colorectal cancer.  
First Author: Jerod J Sears, MD

BOARD F10  ABSTRACT 113: A meta-analysis of bevacizumab’s cardiovascular risks in patients treated for colorectal cancer.  
First Author: Akshit Chitkara, MD

BOARD F11  ABSTRACT 114: Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.  
First Author: Seiichiro Mitani, MD

BOARD F12  ABSTRACT 115: A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers.  
First Author: James J. Harding, MD

BOARD F13  ABSTRACT 116: Phase II evaluation of combination immunotherapy with CV201, N-803, binrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers.  
First Author: Danielle M. Pastor, DO, PhD

BOARD F14  ABSTRACT 117: Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).  
First Author: Ken Kondo, MD

BOARD F15  ABSTRACT 118: Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis.  
First Author: Einat S Shmueli, MD

BOARD F16  ABSTRACT 119: BREAKWATER safety lead-in (SL): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).  
First Author: Scott Kopetz, MD, PhD

BOARD F17  ABSTRACT 120: Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO.  
First Author: Yu Sunakawa, PhD

BOARD F18  ABSTRACT 121: Multicenter retrospective study of trifluridine/tipiracil (FTD/TP) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT).  
First Author: Seiichiro Mitani, MD

BOARD F19  ABSTRACT 122: Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.  
First Author: Deepti Behl, MD
BOARD F20 ABSTRACT 123: Combination treatment of intratumoral vidutolimod (CMP-001), radiosurgery, nivolumab, and ipilimumab for metastatic colorectal carcinoma.
First Author: Yaacov Richard Lawrence, MA, MBBS, MRCP

BOARD G2 ABSTRACT 124: Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CTCG/AGITG CO.17 and CO.20 randomized trials.
First Author: Joao Paulo Solar Vasconcelos, MD

BOARD G3 ABSTRACT 125: Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.
First Author: Xiaojing Xu

BOARD G4 ABSTRACT 126: Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study.
First Author: Ana Fernandez Montes, MD

BOARD G5 ABSTRACT 127: Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic CRC: Analysis of patients treated within the PanaMa trial (AIO KRK 0212).
First Author: Meinolf Karthaus, MD

BOARD G6 ABSTRACT 128: Colorectal endoscopic submucosal dissection using a concealable robotic add-on device: A comparative in vivo feasibility study.
First Author: Sang Hyun Kim, PhD, MD

BOARD G7 ABSTRACT 129: Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
First Author: Stefania Napolitano, MD

BOARD G8 ABSTRACT 130: The EPOCH trial: Identifying key patient subgroups to optimize treatment planning.
First Author: William P. Harris

BOARD G9 ABSTRACT 131: Phase II trial of rosuvastatin combined with chemoradiation therapy (CRT) in the treatment of high-risk locally advanced rectal cancer (STARC trial).
First Author: Jose Gerard Monzon, MD, PhD

BOARD G10 ABSTRACT 132: Efficacy and safety of neoadjuvant preoperative short-course radiation followed by envalofimib plus CAPEOX in microsatellite stable (MSS)/mismatch repair proficient (pMMR) locally advanced rectal cancer.
First Author: Sheng Dai

BOARD G13 ABSTRACT 135: Association of patient and disease characteristics with outcomes of regorafenib in patients with metastatic colorectal cancer.
First Author: Ronan Wenhan Hsieh, MD

BOARD G14 ABSTRACT 136: SOX plus bevacizumab versus SOX plus cetuximab as initial treatment of recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study): A phase II randomized study.
First Author: Shu Okamura, MD, PhD

BOARD G15 ABSTRACT 137: Updated results from ALTER-C001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC.
First Author: Jin Yan

BOARD G16 ABSTRACT 138: Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
First Author: Ke-Feng Ding, MD, PhD

BOARD G17 ABSTRACT 139: A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGFR/FGFR alterations.
First Author: Kristen Keon Ciombor, MD, MS

BOARD G18 ABSTRACT 140: A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (GETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.
First Author: Kanwal Pratap Singh Raghav, MBBS

BOARD G19 ABSTRACT 141: Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study.
First Author: Jenny F. Seligmann, PhD, MRCP, MBChB

BOARD G20 ABSTRACT 142: Outcomes of patients (pts) with metastatic colorectal cancer (mCRC) participating in phase I clinical trials: The Sarah Cannon Research Institute UK experience.
First Author: Ekaterina Ignatova, MD
ABSTRACT 143: Neoadjuvant chemoradiation does not improve outcomes for patients undergoing resection for upper rectal cancer: A US Rectal Cancer Consortium analysis.
First Author: Caroline Medin

ABSTRACT 144: Phase II study of TAS-OX (TAS-102 and oxaliplatin) plus bevacizumab for late-line colorectal cancer.
First Author: Howard S. Hochster, MD

First Author: Emilie A.K. Warren, MD

First Author: Natalia Soledad Tissera

ABSTRACT 147: Phase Ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC; OBERTO-201).
First Author: Joleen M. Hubbard, MD

ABSTRACT 148: Maintenance strategies after anti–EGFR-based induction in RAS wild-type (wt) metastatic colorectal cancer (mCRC): A systematic review and Bayesian network meta-analysis.
First Author: Luca Mastrantoni, MD

ABSTRACT 149: Efficacy and safety of neoadjuvant immune checkpoint inhibitors in patients with localized mismatch repair deficient colorectal cancer: A systematic review.
First Author: Udhayvir Singh Grewal, MD

ABSTRACT 150: Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stable metastatic colorectal cancer (mCRC). Results from the FRUIT trial.
First Author: Xianglin Yuan, Professor

ABSTRACT 151: Antitumor activity of intraperitoneal (IP) paclitaxel to mucinous appendiceal adenocarcinoma in orthotopic patient-derived xenograft model.
First Author: Ichiki Ito, PhD

ABSTRACT 152: Colorectal cohort analysis from the Intraperitoneal Chemotherapy After Cytoreductive Surgery for Peritoneal Metastasis (ICARuS) clinical trial.
First Author: Garrett Michael Nash, MD, MPH

ABSTRACT 153: Identification and external validation of clinical-molecular features to predict benefit from oxaliplatin reintroduction/rechallenge in patients with refractory metastatic colorectal cancer (mCRC).
First Author: Francesc Salva

ABSTRACT 154: Prospective evaluation of dose-escalated preoperative concurrent chemo-radiation with image-guided intensity modulated radiation therapy in locally advanced rectal cancers.
First Author: Raunaq Puri, MBBS

ABSTRACT 155: Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.
First Author: Yungchang Chen

ABSTRACT 156: Frquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial.
First Author: Xianglin Yuan, Professor

ABSTRACT 157: Total neoadjuvant therapy (TNT) for rectal cancer (UICC stages ≥ II): A highly promising approach for long-term survival to all?
First Author: Timotheus Ritter

ABSTRACT 158: A prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma.
First Author: John Paul Y.C. Shen, MD
POSTER SESSION C, continued
BOARD J4: ABSTRACT 164: Extended criteria liver resection: Can noncurative intent resection of colorectal liver metastasis improve survival?
First Author: Jennifer Kalil, MD

BOARD J5: ABSTRACT 165: Total neoadjuvant oxaliplatin-based therapy (TNT) before (induction) and after (consolidation) chemoradiation for advanced rectal cancer: MRI correlation on complete response and outcome.
First Author: Putao Cen, MD

BOARD J6: ABSTRACT 166: A systematic review to assess the efficacy of HER2-targeted treatment regimens in HER2-positive metastatic colorectal cancer (mCRC).
First Author: Muhammad Bakhtiar, MBBS

BOARD J7: ABSTRACT 167: Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.
First Author: Razia Aslam, MBBS

First Author: June Hyuck Lim

BOARD J9: ABSTRACT 169: Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.
First Author: Susanna Slater

BOARD J10: ABSTRACT 170: WU-NK-101, an enhanced memory natural killer (NK) cell therapy, with cetuximab (Ctx) for the treatment of advanced colorectal cancer (CRC).
First Author: John Muth, MSc

BOARD J11: ABSTRACT 171: Impact of Lynch syndrome, BRAF-VRDQE, and RAS mutations on outcomes in MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs): Analysis of combined international cohorts.
First Author: Raphael Colle

BOARD J12: ABSTRACT 172: Prospective observational study of monitoring gene alterations in plasma cell-free DNA using droplet digital PCR system during anti-EGFR antibody treatment in patients with RAS wild-type advanced colorectal cancer.
First Author: Naoki Takahashi, MD, PhD

BOARD J13: ABSTRACT 173: Clinical development and evaluation of plasma angiogenesis factors from phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD): RAINCLOUD-TR.
First Author: Tsuyoshi Hata, MD, PhD

First Author: Thejus Jayakrishnan, MD

BOARD J15: ABSTRACT 175: Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy.
First Author: Michele Ghidini, MD, PhD

First Author: Scarlett Acklin-Wehnert, MD

BOARD J17: ABSTRACT 177: Plasma biomarkers to predict clinical outcomes of FOLFIRI plus ramucirumab (RAM) as second-line treatment for RAS wild-type metastatic colorectal cancer. JACCRO CC-16AR.
First Author: Yu Sunakawa, PhD

BOARD J18: ABSTRACT 178: Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.
First Author: Christos Fountzilas, MD, FACP

BOARD K1: ABSTRACT 179: TP53 gain of function mutation as a prognostic factor in high-methylated metastatic colorectal cancer: Translational research of TRICOLORE study.
First Author: Kota Ouchi, MD, PhD

BOARD K2: ABSTRACT 180: Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial.
First Author: Jonathan M. Loree, MD, MS

First Author: Daniel Kim

First Author: Juanita L. Merchant, MD, PhD
ABSTRACT 183: Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.
First Author: Lucy Xiaolu Ma, MD

ABSTRACT 184: SETD2 gene expression and the molecular landscape of colorectal cancer (CRC).
First Author: Francesca Battaglin, MD

ABSTRACT 185: Molecular correlates of DSCR1 expression in colorectal cancer (CRC).
First Author: Francesca Battaglin, MD

ABSTRACT 186: ctDNA-based fusion detection for advanced colorectal cancer with a partner-agnostic assay.
First Author: Reagan Barnett

ABSTRACT 187: Comparative analysis of tumor immune microenvironment in primary tumors vs metastatic tissue in microsatellite stable metastatic colorectal cancer.
First Author: Marwan Fakih, MD

ABSTRACT 188: Biomarker analysis from a phase I/Ib study of regorafenib and nivolumab (rego/nivo) in microsatellite stable (MSS) colorectal cancer (CRC).
First Author: James Yu, MD

ABSTRACT 189: Use of distinct molecular signatures of appendiceal cancer subtypes to assess biomarker development.
First Author: Wan Ying Tan

ABSTRACT 190: Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).
First Author: Emily Harrold, MBChB

ABSTRACT 191: Tissue assessment of therapeutic responses to neoadjuvant short course radiotherapy with and without anti-CD40 immunotherapy sotigalimab (sotiga) in rectal cancer.
First Author: Todd Anthony Aguilera, MD, PhD

ABSTRACT 192: Circulating tumor cells (CTCs) as liquid biopsies in patients with metastatic colorectal cancer versus other GI malignancies.
First Author: Pashtoon Murtaza Kasi, MD, MSc

ABSTRACT 193: The association between KRAS mutational status, clinicopathological factors including the preoperative systemic inflammatory response and outcomes in TNM stage III colon cancer.
First Author: Allan Matthew Golder, BSc, MBChB, MRCS

ABSTRACT 194: The HORIZON III retrospective exploratory analysis: HER2 expression amplification in colorectal cancer.
First Author: Fabiola Cecchi, PhD, PharmD

ABSTRACT 195: Metagenomic analysis of gut microbiota of patients with colorectal cancer at the Federal Medical Centre (FMC), Abeokuta, Ogun State, Nigeria.
First Author: Lateef Adegboyega Sulaimon

ABSTRACT 196: Tumor mutations associated with outcomes in colorectal peritoneal metastases.
First Author: Abhineet Uppal, MD

First Author: Akira Ouchi, MD, PhD, FACS

ABSTRACT 198: Characterizing the genomic landscape of POLE/POLD1-mutated colorectal adenocarcinoma.
First Author: Tucker Coston, MD

First Author: Michelle Or, MBBS, MMed, FRANZCR

ABSTRACT 200: Use of methylation and fragmentation signals in the detection of early-stage colorectal cancer.
First Author: Pol Canal-Noguer

ABSTRACT 201: Analysis of HLA gene expression in patients with dMMR/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors.
First Author: Heinz-Josef Lenz, MD

ABSTRACT 202: Association between artificial intelligence (AI)-assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC): An observational cohort study.
First Author: Christopher Williams, MBChB, MRCP
ABSTRACT 204: Artificial intelligence-assisted evaluation of tumor infiltrating CD3+ and CD8+ T cells for prognostication and prediction of benefit from adjuvant chemotherapy in early stage colorectal cancer (CRC): A retrospective analysis of the QUASAR trial.
First Author: Christopher Williams, MBChB, MRCP

ABSTRACT 205: Comparison between interval and sporadic colon cancer in terms of clinicopathologic and molecular features.
First Author: Kyu Chan Huh, MD, PhD

ABSTRACT 206: A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.
First Author: Yuri Yoshinami, MD

ABSTRACT 207: Differences in tumor-associated T cell receptor repertoires between young-onset and average-onset colorectal cancer.
First Author: Stephanie Schmit

ABSTRACT 208: Comparative analyses of intratumoral microbiome with diet in patients with early- vs late-onset colorectal cancer.
First Author: Myra E. Green

ABSTRACT 209: Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability.
First Author: J. Randolph Hecht, MD

ABSTRACT 210: Characterizing colorectal cancer (CRC) carriers of the recessive MUTYH founders (G396D/Y179C) and the low-penetrance APC founder APC-I1307K mutation.
First Author: Dong Kim

ABSTRACT 211: Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of prognosis in stage II-III resectable colon cancer.
First Author: Yoojoo Lim, MD

ABSTRACT 212: Assessment of immunoscore and MRI tumor regression grade to predict complete pathologic response in patients with locally advanced rectal cancer: Data from phase II Averectal study.
First Author: Ali Shamseddine, MD, FRCP

ABSTRACT 213: Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for molecular residual disease (MRD) detection in surgical patients with stage I-IV colorectal cancer (CRC).
First Author: Di Cao

ABSTRACT 214: Identification and characterization of four bacteriome- and mycobiome-derived subtypes in tumour and adjacent mucosa tissue of colorectal cancer patients.
First Author: Manuela Salvucci, PhD

ABSTRACT 215: Predicting recurrence in patients with stage II and III colon cancer: Validation cohort and long-term follow-up of the experimental cohort.
First Author: David Virfal

ABSTRACT 216: Mutation status of full RAS and BRAF in 169 Moroccan patients with colorectal cancer.
First Author: Sara El Zaitouni

ABSTRACT 217: Characteristics of immune-infiltrating cells in the tumor microenvironment of appendiceal cancer with peritoneal disease.
First Author: Madeleine Cornelia Strach, FRACP, MBBS, MPH

ABSTRACT 218: Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study.
First Author: Alessandra Anna Prete, MD

ABSTRACT 219: Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.
First Author: Takeshi Yamada, MD

ABSTRACT 220: Association of punctate TAK1 expression with mortality in patients with microsatellite-stable colorectal cancer.
First Author: Norman James Galbraith, PhD MRCS

ABSTRACT 221: Utility of tumor marker levels in predicting survival of patients with appendiceal adenocarcinoma.
First Author: Abdelrahman M.G. Yousef, MD

ABSTRACT 222: Unique microbial biomarkers identified in Nigerian patients with colorectal cancer.
First Author: Miseker Abate, MD

ABSTRACT 223: Goblet cell tumors of the appendix: Clinical and molecular features.
First Author: Abdelrahman M.G. Yousef, MD
BOARD M6 ABSTRACT 224: Tumor mutation burden in colorectal cancers with POLE exonuclease and non-exonuclease domain variants. First Author: Salena Ringenbach

BOARD M7 ABSTRACT 225: Survival of patients with colorectal cancer (CRC) with low expression of homologous recombination proficient (HRP) genes. First Author: Daniel Walden, MD

BOARD M8 ABSTRACT 226: Utility of circulating tumor DNA (ctDNA) in the management of appendiceal adenocarcinoma (AA). First Author: Mohamamd A. Zeineddine, MD

BOARD M9 ABSTRACT 227: A retrospective study of circulating tumor DNA for minimal residual disease detection in the management of colorectal cancer. First Author: Michael H. Storandt, MD

BOARD M10 ABSTRACT 228: Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab. First Author: Ruoyu Miao, MD

BOARD M11 ABSTRACT 229: Serum trefoil factor family 3 as a biomarker for the detection of colorectal cancer. First Author: Hyun Seok Lee, PhD, MD

BOARD M12 ABSTRACT 230: The prediction of pathological complete response after total neoadjuvant therapy for locally advanced rectal cancer using versatile liquid biopsy. First Author: Akihisa Matsuda, MD

BOARD M13 ABSTRACT 231: Comprehensive characterization of KRAS mutations and inter-relation with primary tumor location in colorectal cancers. First Author: Mohamed E. Salem, MD

BOARD M14 ABSTRACT 232: Association of wnt signalling with metachronous colonic polyp risk. First Author: Joanne Edwards, PhD, FRCPath, BSc

BOARD M15 ABSTRACT 233: Neutrophil-to-lymphocyte ratio and clinical outcomes in liver resection for metastatic colorectal cancer. First Author: Sarah Reddy, MD

BOARD M16 ABSTRACT 234: Immunohistochemical assessment of COX2, P53, and beta-catenin expression to predict metachronous lesion development following polyectomy. First Author: Mark Scott Johnstone, MBChB, MRCS, BSc

BOARD M17 ABSTRACT 235: Rectal cancer-specific subtyping using transcriptomics datasets derived from treatment-naive patients to assess novel prognostic signatures and key differences to CMS-based subtyping. First Author: Jochen Prehn, PhD, BPharm

BOARD M18 ABSTRACT 236: Effect of CXCL1 on the NF-κB/P300 signaling pathway and colon cancer progression. First Author: Changhua Zhuo, MD, PhD

BOARD M19 ABSTRACT 237: The role of gene expression of CDC37 in colorectal cancer (CRC). First Author: Hiroyuki Arai, MD, PhD

BOARD M20 ABSTRACT 238: Pathological features associated with lymph node disease in patients with appendiceal neuroendocrine tumors. First Author: Salvador Rodriguez Franco, MD

BOARD N1 ABSTRACT 239: Effect of immunotherapy on the survival outcomes in tumor mutational burden-high (TMB-H) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-institution experience. First Author: Ola Gaber, MD

BOARD N2 ABSTRACT 240: The role of gene expression of CD47 in colorectal cancer (CRC). First Author: Hiroyuki Arai, MD, PhD

BOARD N3 ABSTRACT 241: Delta radiomic parameters for the evaluation of liver metastases in patients with colorectal cancer treated with cetuximab rechallenge plus avelumab in the CAVE mCRC study. First Author: Giulia Martini, MD

BOARD N4 ABSTRACT 242: Effect of dynamic circulating tumor DNA minimal residual disease detection on recurrence surveillance and second resection rate after curative intent resection of colorectal liver metastasis: A prospective cohort study. First Author: Yaqi Li, MD, PhD

BOARD N5 ABSTRACT 243: Tumour radiomics as imaging biomarker of tumour response to chemoradiotherapy in patients with adenocarcinoma of rectum. First Author: Reena Engineer, MD

BOARD N6 ABSTRACT 244: Novel blood-based biomarker candidates in screening for colorectal cancer. First Author: Jason Lee Liggett, PhD

BOARD N7 ABSTRACT 245: Comprehensive characterization of mesothelin expression in colorectal cancer. First Author: Midhun Malla, MD, MS
POSTER SESSION C, continued

First Author: Pashtoon Murtaza Kasi, MD, MSc

First Author: David Viñal

BOARD N10  ABSTRACT 248: Pretreatment risk prediction for distant metastasis in locally advanced rectal cancer.
First Author: Changhoon Song

BOARD N11  ABSTRACT 249: A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).
First Author: Anwaar Saeed, MD

BOARD N12  ABSTRACT 250: Tissue factor expression in colorectal cancer.
First Author: Sandra Algaze, MD

BOARD N13  ABSTRACT 251: Effect of spatial transcriptomic-derived intrinsic epithelial signatures on immune cell recruitment and behaviour in the microenvironment of colorectal cancer.
First Author: Colin Wood, BSc, MBCHB, MRCS

BOARD N14  ABSTRACT 252: AI-powered multi-omic signature to predict treatment response of patients with colorectal cancer liver metastasis.
First Author: Audrey Kapelanski-Lamoureux, PhD

BOARD N15  ABSTRACT 253: A multicenter retrospective cohort study evaluating the clinical significance of CA125 in later line of patients with metastatic colorectal cancer.
First Author: Ken Ito, MD, PhD

First Author: Amos Stemmer

BOARD N17  ABSTRACT 255: Twitterchats as a means to educate patients with CRC and caregivers and stimulate collaborations.
First Author: Manju George, PhD, DVM

BOARD N18  ABSTRACT 256: Lack of hierarchical survival prognosis in AJCC staging for colon cancer: Implications for future summary stage classification.
First Author: Neal Bhutiani, MD, PhD
Saturday, January 21

6:30 AM - 7:55 AM and 12:30 PM - 2:00 PM
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
LEVEL 1, WEST HALL

Posters by Topic
Therapeutics (Colorectal Cancer): N19, N20, P1, P2, P3, P4, P5, P6, P7, P9, P10, P11, P12, P13, P14, P15, P16, P17, P18, P19, P20, Q1, Q2, Q3, Q4, Q5
Other (Colorectal Cancer): Q6

First Author: Robert William Lentz, MD

BOARD N20 ABSTRACT TPS258: NRG-G1004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
First Author: Michael J. Overman, MD

BOARD P1 ABSTRACT TPS259: Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-G1005 (COBRA).
First Author: Van K. Morris II, MD

BOARD P2 ABSTRACT TPS260: NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
First Author: Christopher Hanyoung Lieu, MD

BOARD P3 ABSTRACT TPS261: MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.
First Author: Tanios S. Bekaii-Saab, MD

BOARD P4 ABSTRACT TPS262: A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy.
First Author: Chetan Vakkalagadda, MD

BOARD P5 ABSTRACT TPS263: ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotheraphy in patients with select advanced solid tumors—Colorectal Cancer Cohort (trial in progress).
First Author: Paul Eliezer Oberstein, MD

BOARD P6 ABSTRACT TPS264: TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E–mutant metastatic colorectal cancer.
First Author: Daisuke Kotani, MD

BOARD P7 ABSTRACT TPS265: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E: metastatic and/or unresectable colorectal cancer: SWOG S2107.
First Author: Van K. Morris II, MD

BOARD P9 ABSTRACT TPS267: STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
First Author: J. Randolph Hecht, MD

BOARD P10 ABSTRACT TPS268: SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz, MD, PhD,

First Author: Shunsuke Tsukamoto, MD, PhD

BOARD P12 ABSTRACT TPS270: Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
First Author: Jessica Dreger McDermott, MD, PhD

First Author: Yuki Matsubara, MD
TRIALS IN PROGRESS POSTER SESSION C, continued

BOARD P14  ABSTRACT TPS272: Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti-TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz, MD, PhD

BOARD P15  ABSTRACT TPS273: Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies.
First Author: J. Eva Selfridge, MD

BOARD P16  ABSTRACT TPS274: Phase 1b study to assess the safety of neoadjuvant trifluridine/tipiracil with concurrent radiation in resectable stage II/III rectal cancer.
First Author: Emerson Yu-sheng Chen, MD

BOARD P17  ABSTRACT TPS275: Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
First Author: Zev A. Wainberg, MD

BOARD P18  ABSTRACT TPS276: Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe, MD, PhD

First Author: Neil Howard Segal, MD

BOARD P20  ABSTRACT TPS278: RELATIVITY-123: A phase 3, randomized, open-label study of nivolumab (NIVO) + relatlimab (RELA) fixed-dose combination (FDC) versus regorafenib or trifluridine + tipiracil (TAS-102) in later-line metastatic colorectal cancer (mCRC).
First Author: Kynan Feeney

BOARD Q1  ABSTRACT TPS279: A phase 1b/2, open-label study of avmantanab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.
First Author: Paul Eliezer Oberstein, MD

BOARD Q2  ABSTRACT TPS280: A phase II randomized therapeutic optimization trial for patients with refractory metastatic colorectal cancer using circulating tumor DNA (ctDNA): Rapid 1 trial.
First Author: Sherise C. Rogers, MD, MPH

BOARD Q3  ABSTRACT TPS281: Trial in progress: A phase 2 study of CTX-009 in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens.
First Author: Marilyn Fontaine, BSc

BOARD Q4  ABSTRACT TPS282: Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT).
First Author: Campbell SD Roxburgh, FRCS, PhD

BOARD Q5  ABSTRACT TPS283: Trial in progress: A phase II, multicenter, open-label study of PolyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301).
First Author: Joleen M. Hubbard, MD

BOARD Q6  ABSTRACT TPS284: NSABP C-14: CORRECT-MRD II —Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.
First Author: Mohamed E. Salem, MD
Premium Ancillary Educational Events

The events listed below are hosted independently by other CE-accredited providers and are held adjunct to the ASCO Gastrointestinal Cancers Symposium. Presentations are not official presentations of the GI Symposia and are not sponsored, endorsed or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

**Title:** Case From the Community: Investigators Discuss Available Research Guiding the Care of Patients With Gastroesophageal Cancers

**Date and Time:** Thursday, January 19, 2023; 6:15 PM – 7:45 PM PT (Dinner buffet and registration opens at 5:45 PM PT)

**Location:** San Francisco Marriott Marquis, Golden Gate Ballroom, Salon A (B2 Level)

**CME Provider and Supporter(s):** This event is organized and accredited by Research to Practice and supported through educational grants provided by Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc., and Lilly.

**Registration and Contact Information:** To register for this complimentary event, visit: http://www.ResearchToPractice.com/Meetings/GICancers2023. For additional information, email meetings@researchtopractice.com or call +1(305) 377-2828 / Toll Free (800) 233-6153.

**Event Summary**

This 1.5-hour CME-accredited event (offered in-person and virtually) will focus on the management of patients with gastroesophageal cancers. Research To Practice (RTP) will recruit four clinical investigators with an expertise and/or specialized interest in the management of gastrointestinal cancers to serve as the faculty.

RTP will recruit five U.S.-based community-based general medical oncologists to consult on the program. Each consulting clinician will participate in a one-on-one interview with Dr. Love during which they present current cases from their practices of patients with gastric, gastroesophageal junction or esophageal cancers that require a second opinion from clinical investigators. Excerpts from each videorecorded interview will be selected for presentation during the program.

This event will be divided into four modules. The moderator will introduce select video excerpts from the recorded case presentations and ask the faculty members to comment on the treatment decision-making for the case and reflect on their own clinical experiences caring for similar patients. Following the discussions, a faculty member will deliver a short presentation focused on reviewing relevant scientific knowledge, available data sets and ongoing research related to the topics and cases under review.

In-person and virtual attendees will be able to participate in a premeeting survey related to the topics and cases that will be discussed. Polling results will be interspersed throughout the program to foster additional discussion and further elucidate key knowledge and/or practice gaps among those in attendance. Clinicians will also be encouraged to submit additional questions about their own cases which will be incorporated into the discussion of each module.

**Faculty**

Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center

Florian Lordick, MD, PhD
Leipzig University

Zev Wainberg, MD, MSc
UCLA School of Medicine

Samuel J. Klempner, MD - Moderator
Harvard Medical School

**Title:** Seek and You Will Find: Real-World Strategies to Identify and Target Uncommon but Actionable Genomic Alterations in Advanced Gastrointestinal Cancers

**Date and Time:** Thursday, January 19, 2023; 5:45 PM -7:30 PM PT

**Location:** San Francisco Marriott Marquis, Yerba Buena Ballroom, Salon 7

**CME Provider and Supporter(s):** This event is organized and accredited by PVI, PeerView Institute for Medical Education and supported through an educational grant provided by Lilly.

**Registration and Contact Information:** To register for this event, visit: PeerView.com/GIcancers23-Live. For additional information, email live@peerview.com or call 1-877-833-6141.

**Event Summary:** In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations?

In a new live event from PeerView, a panel of experts in GI malignancies will present evidence-based guidance on modern diagnostic protocols and the personalized treatment of fusion-driven cancers. With relevant cases framing the discussion, the panel will provide foundational knowledge on tumor-agnostic genomic alterations, updates on genomic testing techniques sensitive enough to capture rare alterations, and strategies for integrating targeted agents into treatment plans. If you are
“seeking” out the best information on precision medicine, "find" us in person or online in January.

**Faculty**

Vivek Subbiah, MD  
The University of Texas MD Anderson Cancer Center

Shaalan Beg, MD, MSCS  
University of Texas Southwestern Medical Center

Aparna R. Parikh, MD  
Harvard Medical School, Massachusetts General Hospital Cancer Center

* Additional faculty to be announced

**Title:** The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond

**Date and Time:** Thursday, January 19, 2023; 5:45 - 7:30 PM PT

**Location:** San Francisco Marriott Marquis, Yerba Buena Ballroom, Salons 1-6

**CME Provider and Supporter(s):** This event is organized and accredited by PVI, PeerView Institute for Medical Education and supported by medical education grants from Eisai Inc. and Exelixis, Inc.

**Registration and Contact Information:** To register for this event, visit: PeerView.com/HCC-SF23-Live. For additional information, email live@peerview.com or call 1-877-833-6141.

**Event Summary**

Advances in the management of patients with hepatocellular carcinoma (HCC) have been nothing short of revolutionary. But what does this revolution in care mean for your patients? Join PeerView Live for a MasterClass and Case Forum to learn best practices for providing personalized medicine that incorporates newer TKIs, multikinase inhibitors, and immune checkpoint inhibitors in a variety of settings, including in immunotherapy-based combinations. With discussion of cases drawn from clinical practice, a multidisciplinary panel of experts will link the latest data and research to real-world patient care and provide guidance on using immunotherapy and targeted platforms in the upfront setting, sequencing treatments as patients continue to the second line and beyond, and which emerging strategies are set to bring further changes to HCC outcomes. Join us in person or online as we fight together to help our patients with HCC live longer, healthier lives.

**Faculty**

Ghassan Abou-Alfa, MD, MBA  
Memorial Sloan Kettering Cancer Center

Ahmed Omar Kaseb, MD, CMQ  
The University of Texas MD Anderson Cancer Center

* Additional faculty to be announced

**Title:** Getting Personal With Advanced BTC: Insights on Personalizing Upfront and Sequential Care With Immunotherapy and Targeted Agents

**Date and Time:** Friday, January 20, 2023; 5:30 - 7:15 PM PT

**Location:** San Francisco Marriott Marquis, Yerba Buena Ballroom, Salon 7

**CME Provider and Supporter(s):** This event is organized and accredited by PVI, PeerView Institute for Medical Education, developed in partnership with the Cholangiocarcinoma Foundation, and supported by independent educational grants from AstraZeneca and Incyte Corporation.

**Registration and Contact Information:** To register for this event, visit: PeerView.com/Biliary-SF23-Live. For additional information, email live@peerview.com or call 1.877.833.6141.

**Event Summary**

New science continues to support a modern and diverse management model for advanced biliary tract cancers (BTCs). This new model includes the use of targeted therapies and novel, immune-based platforms for advanced BTCs (culminating with the addition of PD-L1 therapy to first-line cytotoxic regimens); the latter is an advance representing the first meaningful improvement in frontline therapy for advanced/metastatic BTC in over a decade. Collectively, these clinical trends have expanded the use of individualized, sequential management strategies for patients with advanced BTC.

In this PeerView Live Clinical Consults event, expert panelists will provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Using case presentations, this event explores next-generation care for today’s patients with BTC with the use of personalized, upfront treatment management models and sequential management in advanced BTC. Call your GI oncology friends and register today for this cutting-edge educational opportunity!

**Faculty**

Milind Javle, MD  
The University of Texas MD Anderson Cancer Center

Aiwu Ruth He, MD, PhD  
Georgetown University

Rachna T. Shroff, MD, MS  
University of Arizona Cancer Center

**Title:** Cases From the Community: Investigators Discuss Available Research Guiding the Care of Patients With Hepatobiliary Cancers

**Date and Time:** Friday, January 20, 2023; 6:00 PM – 7:30 PM PT  
(Dinner buffet and registration opens at 5:30 PM PT)
**Location:** San Francisco Marriott Marquis, Golden Gate Ballroom, Salon A (B2 Level)

**CME Provider and Supporter(s):** This event is organized and accredited by Research to Practice and supported through educational grants provided by AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation, and Merck.

**Registration and Contact Information:** To register for this complimentary event, visit: http://www.ResearchToPractice.com/Meetings/GlCancers2023. For additional information, email meetings@researchtopractice.com or call +1(305) 377-2828 / Toll Free (800) 233-6153.

**Event Summary**

This 1.5-hour CME-accredited event (offered in-person and virtually) will focus on the management of patients with hepatobiliary cancers. Research To Practice (RTP) will recruit four clinical investigators with an expertise and/or specialized interest in the management of hepatobiliary cancers to serve as the faculty.

RTP will recruit five U.S.-based community-based general medical oncologists to consult on the program. Each consulting clinician will participate in a one-on-one interview with Dr. Love during which they present current cases from their practices of patients with hepatobiliary cancers that require a second opinion from clinical investigators. Excerpts from each videorecorded interview will be selected for presentation during the program.

The event will be divided into four modules. The moderator will introduce video excerpts from the recorded case presentations and ask faculty members to comment on the treatment decision-making for the case and reflect on their own clinical experiences caring for similar patients. Following the discussions, a faculty member will deliver a short presentation focused on reviewing relevant scientific knowledge, available data sets and ongoing research related to the cases under review.

In-person and virtual attendees will be able to participate in a premeeting survey related to the topics and cases that will be discussed. Polling results will be interspersed throughout the program to foster additional discussion and further elucidate key knowledge and/or practice gaps among attendees. Clinicians will be encouraged to submit additional questions about their own cases which will be incorporated into the discussion of each module.

**Faculty**

Richard S. Finn, MD  
David Geffen School of Medicine and Jonsson Comprehensive Cancer Center at UCLA

Lipika Goyal, MD, MPhil  
Harvard Medical School

Arndt Vogel, MD  
Hannover Medical School

Robin K. (Katie) Kelley, MD - Moderator  
University of California, San Francisco
Industry Expert Theater

Industry Expert Theater (IET) sessions, located in the Posters, Exhibits, and Food Room, bring together industry leaders and attendees for 45-minute, nonaccredited educational presentations on the latest in oncology practices, products, services and technologies. If the IET company chooses to post their in-person session recording online, the session audio and slides will be available here for on-demand viewing, within one week of the conclusion of the Symposium. IET sessions are not official presentations of the 2023 ASCO Gastrointestinal Cancers Symposium and are not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer®, the ASCO Foundation. These sessions are not CME-accredited.*

Thursday, January 19

Time: 12:15 PM – 1:00 PM
Title: Applications of Personalized ctDNA Testing to Optimize Treatment Decisions in Patients With GI Cancers
Description: Please join our Industry Expert Theater as we take a closer look at the clinical utility of personalized ctDNA testing for molecular residual disease assessment to address some of the common challenges physicians face when managing their patients with GI cancer.
Company: Natera, Inc.
Presenter: Adham Jurdi, MD—Medical Director, Oncology

Time: 5:00 PM – 5:45 PM
Title: Redefining Cancer Care: The Importance of Genomic-Driven Oncology
Description: A genomic-driven approach to oncology is rapidly evolving. We will discuss the emerging science on genomic alterations, which includes both genetic mutations and pathogenic gene fusions, including NRG1. We will also discuss the benefits of comprehensive RNA-based NGS testing.
Company: Merus
Presenter: Dan Hennessy—Vice President, Medical Affairs

Friday, January 20

Time: 12:15 PM – 1:00 PM
Title: Expanding Treatment Approaches for Unresectable Hepatocellular Carcinoma and Locally Advanced or Metastatic Biliary Tract Cancer
Description: An overview of hepatobiliary cancers followed by summaries of data from the HIMALAYA study of IMFINZI + IMJUDO in unresectable hepatocellular carcinoma and the TOPAZ-1 study of IMFINZI + gemcitabine/cisplatin in locally advanced and metastatic biliary tract cancer.
Company: AstraZeneca
Presenter: Stephen Valerio—U.S. Medical Lead - IO

Time: 4:45 PM – 5:30 PM
Title: PEMAZYRE (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With an FGFR2 Fusion or Rearrangement
Description: Hear Dr. Susan Snodgrass of Incyte present key data from the FIGHT-202 study, a trial evaluating the use of PEMAZYRE in cholangiocarcinoma patients with FGFR2 fusions or rearrangements.

Company: Incyte Corporation
Presenter: Susan Snodgrass, MD—Vice President, U.S. Medical Affairs

*This schedule is subject to change. Information listed is current as of December 7, 2022.

For the most up-to-date information, please visit gi.asco.org.
The exhibits are open on Thursday, January 19 from 7:00 AM – 5:45 PM and Friday, January 20 from 7:00 AM – 5:30 PM in the Posters, Exhibits, and Food Room.

This list of exhibiting companies is subject to change. Information listed is current as of December 7, 2022. The most up-to-date list of exhibitors and a floorplan highlighting the location of each exhibitor is available online at gi.asco.org.

The Exhibitor Directory provides oncologists and other health care professionals with information about companies and their products and services. The Exhibitor Directory does not represent endorsement by the American Society of Clinical Oncology (“ASCO”), either express or implied, of any exhibitor, product, or service. ASCO does not make any warranty concerning the accuracy or reliability of any information contained in this directory and ASCO disclaims any and all responsibility for and liability relating to all such information. The use of the name, logo, or marks of ASCO is strictly prohibited without the prior written consent of ASCO. The information contained in this directory may not be used in any way with or with reference to ASCO’s name, logo, or marks without the prior written consent of ASCO.

If an exhibitor scans your badge, you are sharing your contact data with the exhibitor, and you consent to be contacted by the exhibitor. If you have questions about how an exhibitor uses data, please contact the exhibitor or see their privacy policy.

 nặng™ denotes Conquer Cancer®, the ASCO Foundation Donor and/or Conquer Cancer Council Member as of November 15, 2022.

Aadi Bioscience
Pacific Palisades, CA
312-618-3929
aadibio.com

American Society for Radiation Oncology (ASTRO)
Arlington, VA
703-839-7338
astro.org
The American Society for Radiation Oncology (ASTRO) is the leading society for radiation oncology. We’re dedicated to improving patient care through education and training, support for clinical practice and health policy standards, advancement of science and research and advocacy. Stop by our booth to learn about membership, upcoming meetings, patient education materials specific to GI, APEx - ASTRO’s Accreditation Program for Excellence and RO-ILS: Radiation Oncology Incident Learning System.

Amgen
Thousand Oaks, CA
805-447-1000
amgenoncology.com

ASCO
Alexandria, VA
571-483-1300
asco.org

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are committed to the principle that knowledge conquers cancer and represent nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

Astellas Pharma
Northbrook, IL
312-545-1311
astellas.us

AstraZeneca
Gaithersburg, MD
301-398-0000
astrazeneca-us.com
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to deliver life-changing medicines to patients. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Bayer
Whippany, NJ
862-404-3000
bayer.us

Bayer Medical
Whippany, NJ
862-404-3000
bayer.us

Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT
203-798-4346
us.boehringer-ingelheim.com
At Boehringer Ingelheim we have developed a robust pipeline of homegrown and licensed/partnered clinical assets with a diverse range of modes of actions, including cancer-cell directed and immuno-oncology investigational therapies. We are taking a diligent and broad approach in some of the most challenging, but potentially most impactful, areas of cancer research.

Bristol Myers Squibb
Lawrenceville, NJ
609-302-3000
bms.com
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
CancerLinQ
Alexandria, VA
703-299-0158
cancerlinq.org
Backed by ASCO, CancerLinQ’s products and services reflect a deep understanding of the needs of oncologists, cancer centers, and researchers. We are bilingual by design: fluent in both the language of oncology and technology. As a trusted partner to over 100 cancer centers and community oncology practices, CancerLinQ is uniquely positioned to advance cancer care and research.

Caris Life Sciences
Irving, TX
866-771-8946
CarisLifeSciences.com

Cholangiocarcinoma Foundation Ⓢ
Herriman, UT
888-936-6731
cholangiocarcinoma.org

Colorectal Cancer Alliance
Washington, DC
202-628-0123
ccalliance.org

Crinetics Pharmaceuticals
San Diego, CA
619-821-1884
crinketics.com
Crinetics is a pharmaceutical company that researches, discovers, and develops breakthrough therapies for patients with rare endocrine diseases or tumors. We foster long-term relationships with healthcare practitioners to learn intimately about the challenges patients face every day, then focus on developing game-changing therapies that improve their lives in significant ways.

Daiichi Sankyo Ⓢ
Basking Ridge, NJ
908-992-6400
daichisankyo.com

Deciphera Pharmaceuticals, LLC
Waltham, MA
978-337-7341
deciphera.com

Digestive Care, Inc.
Bethlehem, PA
610-882-5950
digestivecare.com

DNA Genotek Inc.
ON, Canada
613-899-6927
dnagenotek.com

Elevar Therapeutics
Salt Lake City, UT
801-303-7440X300
elevatherapeutics.com

Exelixis, Inc. - Commercial Ⓢ
Alameda, CA
650-837-7000
exelixis.com
Founded in 1994, Exelixis is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. Visit our website to learn more.

Exelixis, Inc. Medical Affairs Ⓢ
Alameda, CA
650-837-7000
exelixismedicalaffairs.com

Facing Our Risk of Cancer Empowered-FORCE
Tampa, FL
866-288-7475
facingourrisk.org/index.php

Ferronova Pty. Ltd
SA, Australia
61-419-862-887
ferronova.com.au

FibroGen
San Francisco, CA
415-815-5891
fibrogen.com

Freenome
South San Francisco, CA
freenome.com

Galera Therapeutics, Inc.
Malvern, PA
610-725-1500
galeratx.com

Genentech
South San Francisco, CA
800-551-2231
gene.com

Global Colon Cancer Association
Washington, DC
610-668-8600
GlobalCCA.org

Guardant Health
Redwood City, CA
855-698-8887
guardanthealth.com
Harborside
Huntington, NY
631-692-0800
harborsidenexus.com
Harborside is a medical communications company and publisher of The ASCO Post, Journal of Oncology Practice, JADPRO and JNCCN. The company also manages the advertising sales for ASCO’s suite of publications, including the Journal of Clinical Oncology (JCO), the Journal of Global Oncology, JCO Clinical Cancer Informatics, and JCO Precision Oncology. In addition, Harborside also produces live events for practicing nurse practitioners, PAs, and pharmacists, including the JADPRO Live conference.

Haystack Oncology
Baltimore, MD
410-348-1918
haystackoncology.com

Hope For Stomach Cancer
Marina del Ray, CA
310-779-4105
stocan.org

Immunovia, Inc.
Marlborough, MA
805-680-2957
immunoviainc.com

Incyte Corporation
Wilmington, DE
302-498-6769
incyte.com

Intera Oncology Inc
Wellesley, MA
617-913-6199
interaoncology.com

Ipsen Biopharmaceuticals
Cambridge, MA
855-463-5127
ipsenvirtualbooth.com

ITM
Charlotte, NC
813-422-2965
itm-radiopharma.com/home

Kinnate Biopharma
San Diego, CA
858-299-4699
kinnate.com

KRAS Kickers
Charlotte, NC
704-299-0814
kraskickers.org

Loxo @ Lilly
Indianapolis, IN
317-276-2000
lilly.com

Merck & Co.
Kenilworth, NJ
908-423-1000
merck.com

Merus
Cambridge, MA
617-401-4499
merus.nl

Mirati Therapeutics
San Diego, CA
858-332-3410
mirati.com

My Faulty Gene
Grand Saline, TX
903-747-2687
myfaultygene.org

My Gut Feeling – Stomach Cancer Foundation of Canada
ON, Canada
647-478-5414
mygutfelling.ca
My Gut Feeling is the only non-profit in Canada that directly supports stomach cancer patients, survivors and caregivers through peer-to-peer support, education, awareness and advocacy. It was founded by two survivors in 2016 and is a volunteer-led organization. Our work includes monthly patient support groups, annual conferences, webinar education series, patient advocacy through membership on international research projects, and the establishment of Stomach Cancer Awareness Day (November 30).

Natera, Inc.
Austin, TX
650-249-9090
natera.com/oncology

National Pancreas Foundation
Bethesda, MD
301-961-1508
pancreasfoundation.org

Neogenomics Laboratories
Fort Myers, FL
239-768-0600
neogenomics.com

Neuroendocrine Cancer Awareness Network
Fort Mill, SC
866-850-9555
netcancerawareness.org

Novartis
East Hanover, NJ
917-282-4713
adacap.com
Novocure Inc.
Portsmouth, NH
917-270-9770
novocure.com
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, TTFields. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.

One Cancer Place
Denver, CO
303-780-9111
onecancerplace.org/index.html

Paltown Development Foundation
Crownsville, MD
410-849-9660
paltown.org

Pfizer Oncology
New York, NY
212-733-2323
pfizeroncologydevelopment.com

Pfizer Oncology – Medical
New York, NY
212-733-2323
pfizeroncologydevelopment.com
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

Replimune
Woburn, MA
202-930-4762
replimune.com

Seagen Commercial
Bothell, WA
425-527-4000
seagen.com

Seagen Medical Affairs
Bothell, WA
425-527-4000
seagenmedicalaffairs.com

SERVIER
Suresnes, Ile-de-France
servier.com/en/

Servier Pharmaceuticals
Boston, MA
310-200-0237
servier.us

Sirtex
Woburn, MA
888-474-7839
sirtex.com

Society of Surgical Oncology
Rosemont, IL
847-427-1400
surgonc.org
The Society of Surgical Oncology is a global community of cancer surgeons shaping advancements in the profession to deliver the highest quality surgical care. SSO promotes leading-edge research, quality standards and knowledge exchange, connecting cancer surgeons worldwide to continuously improve cancer outcomes. The International Conference on Surgical Cancer Care (March 2023) presents collective wisdom to effect change and the Annals of Surgical Oncology is the leading resource in surgical oncology.

STERIS Corporation
Mentor, OH
800-548-4873
steris.com/endoscopy

Taiho Oncology - Commercial
Princeton, NJ
609-613-7884
taihooncology.com

Taiho Oncology Inc (Medical)
Princeton, NJ
609-613-7884
taihooncology.com

Tempus
Chicago, IL
833-514-4187
tempus.com

TransThera Sciences (Nanjing), Inc.,
Jiangsu, China
86-25-58216200
transtherabio.com/En/Index/index.html
TransThera Sciences, Inc. is a biopharmaceutical company based in Nanjing, China and now in the United States. We are committed to fulfilling global significant unmet medical needs through in-house R&D and innovation and dedicated to discovering and developing the next generation of innovative targeted therapies for oncology, inflammatory, and cardiovascular diseases. Our current pipeline includes global trials in CCA and BTC among other oncology and non-oncology indications.

TriSalus Life Sciences
Westminster, CO
724-612-8584
trisaluslifesci.com

ViewRay, Inc.
Denver, CO
719-323-0391
viewray.com